{"timestamp": "2026-01-21T07:03:43.290512", "question": "{\"CASE_CORE\":{\"ADJUVANT_TREATMENT\":{\"cycles_or_courses\":\"6\",\"given\":\"Yes\",\"regimens\":[\"白紫+卡铂\"]},\"BIOMARKERS\":{\"AFP\":\"<0.91 ng/ml (2022-10-12)\",\"CA125\":\"933.00 U/ml (2022-12-29)\",\"HER2\":\"Unknown\",\"MSI\":\"Unknown\",\"PDL1_CPS\":\"Unknown\",\"TMB\":\"Unknown\"},\"BRCA1\":\"Unknown\",\"BRCA2\":\"Unknown\",\"CURRENT_STATUS\":\"Recurrent ovarian clear cell carcinoma with metastatic disease (liver, presacral/sacrum, right iliac bone) documented on imaging\",\"DIAGNOSIS\":{\"components\":[\"High-grade adenocarcinoma involving full-thickness intestinal wall\",\"Lymph node metastasis (4/15)\",\"Peritoneal/rectal/vaginal involvement described\"],\"histology\":\"透明细胞癌; 肠壁全层见高级别腺癌\",\"laterality\":\"Unknown\",\"primary\":\"卵巢癌复发\",\"site\":\"Ovary\"},\"HRD\":\"Unknown\",\"INITIAL_TREATMENT\":\"Unknown\",\"LINE_OF_THERAPY\":[{\"cycles\":\"6\",\"end_date\":\"2022-08-17\",\"intent\":\"Unknown\",\"line\":\"1L\",\"regimen\":\"白紫+卡铂\",\"start_date\":\"Unknown\"}],\"MAINTENANCE\":\"Unknown\",\"MAINTENANCE_DETAIL\":{\"end_date\":\"Unknown\",\"given\":\"Unknown\",\"regimens\":[],\"start_date\":\"Unknown\"},\"NEOADJUVANT\":\"Unknown\",\"PFI_days\":\"56\",\"PLATINUM_HISTORY\":[{\"PFI_days\":\"56\",\"end_date\":\"2022-08-17\",\"evidence\":\"Rise in CA125/CA19-9 on 2022-10-12\",\"evidence_type\":\"Biochemical\",\"first_relapse_date\":\"2022-10-12\",\"line\":\"1L\",\"start_date\":\"Unknown\",\"status\":\"Resistant\"}],\"PLATINUM_PFI_CURRENT\":\"56\",\"PLATINUM_STATUS\":\"Resistant\",\"PLATINUM_STATUS_CURRENT\":\"Resistant\",\"RELAPSE\":\"Yes\",\"RELAPSE_DATE\":{\"date\":\"2022-10-12\",\"evidence\":\"Elevated CA125 and CA19-9 on 2022-10-12; imaging (MRI 2022-10-24, CT 2022-10-25) supports recurrence\",\"type\":\"Biochemical\"},\"SCENE\":\"Platinum_resistant_relapse\",\"STAGE\":{\"stage_basis\":\"Unknown\",\"stage_system\":\"Unknown\",\"stage_text\":\"Unknown\"},\"SURGERY_DONE\":{\"date\":\"2022-03-28\",\"performed\":\"Yes\",\"procedure\":\"Tumor debulking + partial rectosigmoid resection + partial vaginectomy + retroperitoneal lesion resection + complex adhesiolysis + left ureteral stent placement + bladder repair\"},\"TIMELINE\":{\"constraints\":{\"max_events\":30,\"min_events\":3,\"must_include\":[\"first diagnostic imaging or pathology confirmation (if available)\"],\"ordering_rules\":{\"prioritize_last_event\":true}},\"events\":[{\"date\":\"2022-03-28\",\"description\":\"Cytoreductive surgery including partial rectosigmoid resection, partial vaginectomy, retroperitoneal lesion resection, left ureteral stent, bladder repair\",\"event_type\":\"Surgery\",\"key_result\":\"Tumor ~7x4x2.5 cm; full-thickness intestinal wall high-grade adenocarcinoma; consider ovarian clear cell carcinoma; 4/15 nodes positive\",\"regimen_or_test\":\"Surgical resection\"},{\"date\":\"2022-08-17\",\"description\":\"Completed 6 cycles of 白紫+卡铂 chemotherapy, last given 2022-08-17\",\"event_type\":\"Chemo\",\"key_result\":\"Post-chemo tumor markers reduced on 2022-08-15\",\"regimen_or_test\":\"白紫+卡铂\"},{\"date\":\"2022-10-12\",\"description\":\"Rising tumor markers indicating recurrence\",\"event_type\":\"Lab\",\"key_result\":\"CA19-9 77.20 U/ml; CA125 89.60 U/ml\",\"regimen_or_test\":\"Tumor markers\"},{\"date\":\"2022-10-24\",\"description\":\"Pelvic MRI shows presacral mass and pelvic mesenteric nodules; consider recurrence with sacral involvement\",\"event_type\":\"Imaging\",\"key_result\":\"Presacral lesion and pelvic mesenteric nodules, possible metastases\",\"regimen_or_test\":\"MRI pelvis\"},{\"date\":\"2022-10-25\",\"description\":\"CT shows multiple liver nodules, some new compared to prior\",\"event_type\":\"Imaging\",\"key_result\":\"Multiple hepatic metastatic nodules\",\"regimen_or_test\":\"CT abdomen\"},{\"date\":\"2022-12-29\",\"description\":\"Markedly elevated tumor markers consistent with progression\",\"event_type\":\"Lab\",\"key_result\":\"CA125 933.00 U/ml; CA19-9 229.00 U/ml; HE4 111.00 pmol/L\",\"regimen_or_test\":\"Tumor markers\"},{\"date\":\"2022-12-30\",\"description\":\"MRI/CT show increased presacral lesion, new right iliac bone nodule, increased hepatic metastases\",\"event_type\":\"Imaging\",\"key_result\":\"Progression of pelvic and hepatic metastatic disease\",\"regimen_or_test\":\"MRI pelvis; CT abdomen\"}]},\"VISIT_DATE\":\"2023-01-03\",\"first_relapse_date\":\"2022-10-12\",\"last_platinum_end_date\":\"2022-08-17\"},\"LAB_TRENDS\":{\"labs\":[{\"analyte\":\"CA125\",\"history\":[{\"date\":\"2022-08-15\",\"flag\":\"Unknown\",\"value\":\"14.90\"},{\"date\":\"2022-10-12\",\"flag\":\"↑\",\"value\":\"89.60\"},{\"date\":\"2022-11-17\",\"flag\":\"↑\",\"value\":\"403\"},{\"date\":\"2022-12-29\",\"flag\":\"↑\",\"value\":\"933.00\"}],\"latest\":{\"date\":\"2022-12-29\",\"flag\":\"↑\",\"value\":\"933.00\"},\"reference_range\":\"Unknown\",\"unit\":\"U/ml\"},{\"analyte\":\"CA19-9\",\"history\":[{\"date\":\"2022-08-15\",\"flag\":\"Unknown\",\"value\":\"7.16\"},{\"date\":\"2022-10-12\",\"flag\":\"↑\",\"value\":\"77.20\"},{\"date\":\"2022-12-29\",\"flag\":\"↑\",\"value\":\"229.00\"}],\"latest\":{\"date\":\"2022-12-29\",\"flag\":\"↑\",\"value\":\"229.00\"},\"reference_range\":\"Unknown\",\"unit\":\"U/ml\"},{\"analyte\":\"HE4\",\"history\":[{\"date\":\"2022-08-15\",\"flag\":\"↑\",\"value\":\"87.90\"},{\"date\":\"2022-10-12\",\"flag\":\"Unknown\",\"value\":\"59.70\"},{\"date\":\"2022-12-29\",\"flag\":\"↑\",\"value\":\"111.00\"}],\"latest\":{\"date\":\"2022-12-29\",\"flag\":\"↑\",\"value\":\"111.00\"},\"reference_range\":\"Unknown\",\"unit\":\"pmol/L\"},{\"analyte\":\"AFP\",\"history\":[{\"date\":\"2022-10-12\",\"flag\":\"Unknown\",\"value\":\"<0.91\"}],\"latest\":{\"date\":\"2022-10-12\",\"flag\":\"Unknown\",\"value\":\"<0.91\"},\"reference_range\":\"Unknown\",\"unit\":\"ng/ml\"}],\"milestones\":[{\"date\":\"2022-03-28\",\"description\":\"Primary cytoreductive surgery performed\",\"type\":\"Surgery\"},{\"date\":\"2022-08-17\",\"description\":\"Completed 6 cycles of 白紫+卡铂\",\"type\":\"ChemoEnd\"},{\"date\":\"2022-10-12\",\"description\":\"Biochemical relapse with rising tumor markers\",\"type\":\"Relapse\"}]},\"MED_ONC\":{\"current_regimen\":{\"cycle_info\":\"6 cycles of 白紫+卡铂, last 2022-08-17\",\"last_admin_date\":\"2022-08-17\",\"name\":\"Unknown\"},\"genetic_testing\":{\"germline\":[],\"somatic\":[]},\"monitoring_points\":[],\"planned_next_regimen\":\"Unknown\",\"prior_systemic_therapies\":[\"白紫+卡铂\"]},\"NUC_MED\":{\"studies\":[]},\"PATHOLOGY\":{\"specimens\":[{\"components\":[\"Tumor size ~7x4x2.5 cm\",\"Bilateral margins negative\",\"Pericolic lymph nodes 4/15 positive\",\"One tumor nodule (posterior bladder)\"],\"date\":\"2022-03-28\",\"diagnosis\":\"Consider ovarian clear cell carcinoma involvement; full-thickness intestinal wall high-grade adenocarcinoma\",\"grade\":\"High-grade\",\"ihc\":[{\"marker\":\"MLH1\",\"result\":\"+\"},{\"marker\":\"MSH6\",\"result\":\"+\"},{\"marker\":\"MSH2\",\"result\":\"+\"},{\"marker\":\"PMS2\",\"result\":\"+\"},{\"marker\":\"ER\",\"result\":\"partial+\"},{\"marker\":\"PR\",\"result\":\"few weak+\"},{\"marker\":\"P53\",\"result\":\"+/-\"},{\"marker\":\"WT1\",\"result\":\"-\"},{\"marker\":\"Ki-67\",\"result\":\"60%+\"},{\"marker\":\"HNF1B\",\"result\":\"+\"},{\"marker\":\"NapsinA\",\"result\":\"focal+\"},{\"marker\":\"P16\",\"result\":\"+\"},{\"marker\":\"PAX8\",\"result\":\"+\"},{\"marker\":\"SALL4\",\"result\":\"-\"},{\"marker\":\"ZBTB16\",\"result\":\"-\"}],\"involvement_sites\":[\"Rectosigmoid colon\",\"Left retroperitoneum\",\"Vagina\",\"Pericolic lymph nodes\",\"Posterior bladder nodule\"],\"laterality\":\"Unknown\",\"molecular\":[],\"raw_text\":\"卵巢恶性肿瘤：卵巢癌复发：术前CA125 45.7 CA199 161 HE4 562 2022.03.28在全麻下行“瘤体减灭术+直肠乙状结肠部分切除术+阴道部分切除术+腹膜后病损切除术+复杂肠粘连松解术+左输尿管支架置管术+膀胱修补术。（部分直乙结肠+左侧腹膜后肿瘤+部分阴道）肠壁全层见高级别腺癌，结合T2022-04771首先考虑为透明细胞癌，正在加做免疫组化进一步明确。肿块大小约7*4*2.5cm。双侧切缘阴性，肠周淋巴结（4/15）见癌转移，伴癌结节1枚。（膀胱后壁肿瘤）纤维脂肪组织，局灶纤维组织增生、含铁血黄素沉积、泡沫样组织反应，未见癌累及。补充诊断1：【补充报告】（部分直乙结肠+左侧腹膜后肿瘤+部分阴道）可符合卵巢透明细胞癌累及。免疫组化（HI22-06789）瘤细胞：MLH1(ES05)（+），MSH6（+），MSH2（+），PMS2（+），ER（部分+），PR（少弱+），P53（+/-），WT1（-），Ki-67（60%+），HNF1B（+），NapsinA（灶+），P16（+），PAX8（+），SALL4（-），ZBTB16（-）\",\"sample_type\":\"Surgical resection\",\"site\":\"Partial rectosigmoid + left retroperitoneal tumor + partial vagina\",\"tumor_size\":\"7 x 4 x 2.5 cm\",\"uncertainty_or_missing\":[\"BRCA/HRD testing not reported\"]}]},\"RADIOLOGY\":{\"next_imaging_plan\":{\"modality\":\"Unknown\",\"timing\":\"Unknown\"},\"studies\":[{\"anatomic_sites\":[\"Pelvis\"],\"date\":\"2022-10-24\",\"findings\":[\"Postoperative pelvis with presacral mass; pelvic mesenteric multiple enhancing small nodules\"],\"impression\":\"Consider recurrence with adjacent sacral involvement; pelvic mesenteric nodules likely metastases\",\"modality\":\"MRI\",\"trend_vs_prior\":\"Unknown\"},{\"anatomic_sites\":[\"Liver\"],\"date\":\"2022-10-25\",\"findings\":[\"Multiple intrahepatic nodules, some new compared to prior\"],\"impression\":\"Probable metastases in liver\",\"modality\":\"CT\",\"trend_vs_prior\":\"Worse\"},{\"anatomic_sites\":[\"Pelvis; sacrum; right iliac bone\"],\"date\":\"2022-12-30\",\"findings\":[\"Presacral lesion increased in size and heterogeneous enhancement; right iliac bone new enhancing nodule; pelvic mesenteric nodules similar\"],\"impression\":\"Progression of presacral disease with possible sacral and iliac bone involvement; peritoneal metastases possible\",\"modality\":\"MRI\",\"trend_vs_prior\":\"Worse\"},{\"anatomic_sites\":[\"Liver; spleen\"],\"date\":\"2022-12-30\",\"findings\":[\"Multiple hepatic metastatic nodules increased in number and size; splenic patchy shadow suggesting possible infarct\"],\"impression\":\"Progression of hepatic metastases\",\"modality\":\"CT\",\"trend_vs_prior\":\"Worse\"}]},\"TIMELINE\":{\"constraints\":{\"max_events\":30,\"min_events\":3,\"must_include\":[\"first diagnostic imaging or pathology confirmation (if available)\"],\"ordering_rules\":{\"prioritize_last_event\":true}},\"events\":[{\"date\":\"2022-03-28\",\"description\":\"Cytoreductive surgery including partial rectosigmoid resection, partial vaginectomy, retroperitoneal lesion resection, left ureteral stent, bladder repair\",\"event_type\":\"Surgery\",\"key_result\":\"Tumor ~7x4x2.5 cm; full-thickness intestinal wall high-grade adenocarcinoma; consider ovarian clear cell carcinoma; 4/15 nodes positive\",\"regimen_or_test\":\"Surgical resection\"},{\"date\":\"2022-08-17\",\"description\":\"Completed 6 cycles of 白紫+卡铂 chemotherapy, last given 2022-08-17\",\"event_type\":\"Chemo\",\"key_result\":\"Post-chemo tumor markers reduced on 2022-08-15\",\"regimen_or_test\":\"白紫+卡铂\"},{\"date\":\"2022-10-12\",\"description\":\"Rising tumor markers indicating recurrence\",\"event_type\":\"Lab\",\"key_result\":\"CA19-9 77.20 U/ml; CA125 89.60 U/ml\",\"regimen_or_test\":\"Tumor markers\"},{\"date\":\"2022-10-24\",\"description\":\"Pelvic MRI shows presacral mass and pelvic mesenteric nodules; consider recurrence with sacral involvement\",\"event_type\":\"Imaging\",\"key_result\":\"Presacral lesion and pelvic mesenteric nodules, possible metastases\",\"regimen_or_test\":\"MRI pelvis\"},{\"date\":\"2022-10-25\",\"description\":\"CT shows multiple liver nodules, some new compared to prior\",\"event_type\":\"Imaging\",\"key_result\":\"Multiple hepatic metastatic nodules\",\"regimen_or_test\":\"CT abdomen\"},{\"date\":\"2022-12-29\",\"description\":\"Markedly elevated tumor markers consistent with progression\",\"event_type\":\"Lab\",\"key_result\":\"CA125 933.00 U/ml; CA19-9 229.00 U/ml; HE4 111.00 pmol/L\",\"regimen_or_test\":\"Tumor markers\"},{\"date\":\"2022-12-30\",\"description\":\"MRI/CT show increased presacral lesion, new right iliac bone nodule, increased hepatic metastases\",\"event_type\":\"Imaging\",\"key_result\":\"Progression of pelvic and hepatic metastatic disease\",\"regimen_or_test\":\"MRI pelvis; CT abdomen\"}]}}", "final_output": "Final Assessment:\nHigh‑grade ovarian clear cell carcinoma, platinum‑resistant, with progressive hepatic and presacral/sacral/iliac bone metastases and severe anemia; main uncertainties are performance status, anemia etiology, and trial options.\n\nCore Treatment Strategy:\n- Immediately investigate and correct anemia (iron/B12/folate, hemolysis, transfusion as needed) before further systemic therapy [@20230103|5600862 | LAB].  \n- Document ECOG status, pain (including bone/neurologic), and prior toxicity to define feasible non‑platinum relapse‑therapy intensity [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 10].  \n- Plan non‑platinum systemic relapse therapy for platinum‑resistant clear cell disease once optimized; parallelly screen for eligible phase Ib/II trials [@OH2203828 | Genomics][@pubmed | 30109783][@trial | 350].  \n- Use 2022‑12‑29 CT/MR as staging baseline; repeat CT/MR if clinical status changes, reserving PET‑CT only if results would alter systemic or palliative local strategies [@2022-12-29|MR | MR][@2022-12-29|CT | CT][@guideline:esgo_esmo_esp_consensus_ovariancancer_2024__v00000000 | Page 8].  \n\nChange Triggers:\n- If anemia persists or worsens despite work‑up/treatment, delay or de‑escalate systemic therapy intensity and prioritize supportive measures.  \n- If new focal bone/neurologic symptoms or rapid marker rise occur, obtain urgent targeted imaging and consider palliative radiotherapy or adjusted systemic approach.\n\n---\n## References\n\n### Guidelines\n\n[@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 10]\n  Document: esmo_cpg_epithelialovarian_2023__v00000000, Page 10\n  Content: with ﬁrst line. This can probably be explained by an...\n\n[@guideline:esgo_esmo_esp_consensus_ovariancancer_2024__v00000000 | Page 8]\n  Document: esgo_esmo_esp_consensus_ovariancancer_2024__v00000000, Page 8\n  Content: [III, B].\nConsensus: 97% (34) yes, 0% (0) no, 3% (1)...\n\n### Literature\n\n[@pubmed | 30109783]\n  PMID: 30109783 | Cancer Med | 2018-09-01\n  Title: Characterization and drug sensitivity of a novel human ovarian clear cell carcinoma cell line genomically and phenotypically similar to the original tumor.\n  DOI: 10.1002/cam4.1724\n\n### Clinical Trials\n\n[@trial | 350]\n  Trial ID: 350\n  Name: 评价注射用BL-B01D1在复发或转移性妇科恶性肿瘤等多种实体瘤患者中的安全性、耐受性、药代动力学及有效性的Ib/II期临床研究\n  Rationale: Recurrent metastatic ovarian clear cell carcinoma is a gynecologic malignancy after ≥1 prior standard therapy, matching this 2L–3L gynecologic trial without biomarker requirements.\n\n### Clinical Reports\n\n[@20230103|5600862 | LAB]\n  LAB ID: 20230103|5600862 | Date: 2023-01-03\n  Content: 中性粒细胞% 76.5 % (GRAN) PLT分布宽度 12 % (PDW) 嗜碱性细胞数 0.01 *10^9/L...\n\n[@OH2203828 | Genomics]\n  Genomics ID: OH2203828 | Date: 2022-04-18\n  Content: ATM NM_000051:exon8:c.A947G:p.Y316C（胚系）；HRD 阴性；BRCA1...\n\n[@2022-12-29|MR | MR]\n  MR ID: 2022-12-29|MR | Date: 2022-12-29\n  Content: 对比前片2022-10-21：盆腔术后，阴道残端略厚，骶前见不规则肿块影，较前增大，目前范围约53×44mm，信号较前不...\n\n[@2022-12-29|CT | CT]\n  CT ID: 2022-12-29|CT | Date: 2022-12-29\n  Content: 对比前片2022-10-21：肝内多发低密度结节，较前增多，部分较前增大，大者约17m*14mm，部分较前新见。肝内另见...\n", "initial_ops": {"chair": "- Platinum‑resistant metastatic clear cell ovarian carcinoma with rapid progression in liver, presacral/sacral and bone; systemic non‑platinum regimen indicated [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 10].  \n\n- Baseline anemia (Hgb 74 g/L) requires correction and transfusion/iron assessment before starting further systemic therapy [@20230103|5600862 | LAB].  \n\n- Before firm plan: document ECOG status, pain/skeletal symptoms, prior toxicities, and confirm current MRI/CT images and full NGS interpretation details [@OH2203828 | Genomics].", "oncologist": "- Platinum-resistant recurrent clear cell ovarian carcinoma with rising CA125/CA19-9 and new liver/bone metastases; systemic relapse-therapy category indicated. [@20221229|9703212 | LAB] [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 10]  \n\n- Significant anemia (Hgb 74 g/L) may limit intensity of cytotoxic systemic therapy; requires optimization/transfusion before full-dose treatment. [@20230103|5600862 | LAB]  \n\n- Organ function (renal/hepatic) appears acceptable for most systemic options; confirm current performance status and recent cross-sectional imaging details for planning. [@20221229|8300002 | LAB]", "radiologist": "- Progressive presacral pelvic mass with sacral and right iliac bone involvement; multiple stable pelvic mesenteric/peritoneal nodules suspicious for metastases [@2022-10-24|MR | MR] [@2022-12-29|MR | MR].  \n\n- Liver: multiple metastatic nodules increasing in number and size; spleen with patchy low‑density area possibly infarct, needs clinical correlation [@2022-12-29|CT | CT].  \n\n- Cross‑sectional CT/MRI adequately demonstrate advanced, recurrent disease distribution for MDT treatment planning [@guideline:esgo_esmo_esp_consensus_ovariancancer_2024__v00000000 | Page 8].", "pathologist": "- Morphology and IHC strongly support recurrent ovarian clear cell carcinoma involving rectosigmoid, retroperitoneum, and vagina, high‑grade. [@guideline:esgo_esmo_esp_consensus_ovariancancer_2024__v00000000 | Page 6]\n\n- MMR proteins intact; no evidence of MMR deficiency/MSI‑H on IHC. [@2022-03-28 | LAB]\n\n- Comprehensive NGS: germline ATM p.Y316C; BRCA1/2 and HRD negative; no other pathogenic HRR variants detected. [@OH2203828 | Genomics]", "nuclear": "- Known pelvic presacral mass with sacral and right iliac bone involvement; PET could better define osseous/metastatic extent and activity [@2022-12-29|MR | MR].\n\n- Progressive multifocal hepatic metastases on CT; PET would refine whole‑body metastatic burden and extrahepatic disease mapping [@2022-12-29|CT | CT].\n\n- For advanced/recurrent ovarian carcinoma, PET‑CT is an acceptable staging option complementing MRI/CT for planning [@guideline:esgo_esmo_esp_consensus_ovariancancer_2024__v00000000 | Page 8]."}, "merged_summary": "Key Knowledge:\n- Platinum‑resistant recurrent high‑grade clear cell ovarian carcinoma with rapid systemic progression (liver, presacral/sacral, pelvic bone, peritoneal nodules).\n- Rising CA125/CA19‑9 consistent with radiologic progression.\n- Significant anemia (Hgb 74 g/L) requiring correction; renal/hepatic function acceptable for systemic therapy once optimized.\n- Histology/IHC confirm pure high‑grade ovarian clear cell carcinoma; MMR proficient (MLH1/MSH2/MSH6/PMS2 retained), ER/PR focally expressed; BRCA1/2 and HRD negative; germline ATM p.Y316C variant noted.\n- Current staging is based on 2022‑12‑29 CT/MR showing progressive liver and presacral/sacral disease; PET‑CT not yet performed and considered only if management‑altering.\n\nControversies:\n- Optimal non‑platinum relapse regimen and intensity for platinum‑resistant clear cell histology in the setting of severe baseline anemia.\n- Threshold for ordering PET‑CT versus repeating CT/MR alone, and whether PET findings would realistically change systemic versus palliative local strategies.\n- Clinical actionability and trial relevance of the germline ATM variant in this patient’s context.\n\nMissing Info:\n- ECOG performance status and detailed symptom burden (pain, skeletal, neurologic, functional impact).\n- Full prior treatment toxicity history and current medications.\n- Confirmation that no post‑2022‑12‑29 CT/MRI exists; need for updated cross‑sectional imaging if disease status is uncertain.\n- Integrated NGS/molecular addendum summarizing HRD‑negative, BRCA‑wild‑type status and detailed classification/implications of ATM p.Y316C.\n- Current anemia work‑up (iron/B12/folate, hemolysis markers) and transfusion/iron replacement history.\n\nWorking Plan:\n- Correct severe anemia and complete anemia work‑up; then reassess suitability for full‑dose non‑platinum systemic therapy.\n- Document ECOG, symptom burden (including bone/neurologic symptoms), and prior toxicities to individualize relapse systemic regimen and supportive care.\n- Confirm absence of more recent imaging; update staging with new CT/MR if prior (2022‑12‑29) set is outdated or discordant with current symptoms.\n- Consider FDG PET‑CT only if additional disease mapping would change systemic regimen choice, clinical trial eligibility, or local palliative interventions (e.g., radiotherapy targeting).\n- Finalize pathology/molecular documentation: issue addendum confirming pure clear cell histology, MMR proficiency, ER/PR status, and integrated summary of HRD‑negative, BRCA‑wild‑type, and ATM variant, to support systemic and trial planning.", "final_round_ops": {"Round 1": {"chair": "- Correct severe anemia and clarify ECOG, symptom burden, prior toxicities before initiating any non‑platinum systemic therapy [@20230103|5600862 | LAB].  \n\n- Proceed with non‑platinum systemic regimen suitable for platinum‑resistant clear cell disease once optimized, considering trial options and ATM‑related eligibility [@OH2203828 | Genomics][@pubmed | 30109783].  \n\n- Update staging with latest CT/MRI; add PET‑CT only if results would change systemic versus palliative local strategy [@2022-12-29|MR | MR][@2022-12-29|CT | CT][@guideline:esgo_esmo_esp_consensus_ovariancancer_2024__v00000000 | Page 8].", "oncologist": "- Correct anemia and document ECOG, symptom burden, and prior toxicities before initiating individualized non‑platinum relapse systemic therapy. [@20230103|5600862 | LAB] [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 10]  \n\n- Proceed with systemic relapse‑therapy planning assuming clear cell histology, MMR proficiency, BRCA/HRD negativity, and germline ATM variant per NGS. [@OH2203828 | Genomics] [@pubmed | 30109783]  \n\n- Confirm no post‑2022‑12‑29 CT/MRI; order PET‑CT only if results would modify systemic choice or local palliative interventions. [@2022-12-29|MR | MR] [@2022-12-29|CT | CT]", "radiologist": "- No cross‑sectional imaging is available after 2022‑12‑29; current staging relies on that CT/MR set [@2022-12-29|MR | MR] [@2022-12-29|CT | CT].  \n\n- Before PET‑CT, clarify whether updated CT/MR is planned; PET should be reserved for scenarios where it may alter management [@guideline:esgo_esmo_esp_consensus_ovariancancer_2024__v00000000 | Page 8].  \n\n- Document any new focal bone or neurologic symptoms to prioritize targeted imaging (e.g., spine/pelvis MRI) if clinically indicated [@2022-12-29|MR | MR].", "pathologist": "- Confirm final histology as pure high‑grade ovarian clear cell carcinoma; no morphologic evidence of mixed or alternative histotype. [@guideline:esgo_esmo_esp_consensus_ovariancancer_2024__v00000000 | Page 6]\n\n- Clearly state MMR proficiency (MLH1/MSH2/MSH6/PMS2 retained) and ER/PR focal expression in the pathology addendum. [@2022-03-28 | LAB]\n\n- Request integrated molecular addendum summarizing HRD‑negative, BRCA‑wild‑type status and detailing germline ATM p.Y316C classification/implications. [@OH2203828 | Genomics]", "nuclear": "- No PET-CT yet; recommend whole‑body FDG PET-CT only if updated mapping would alter local palliation or systemic strategy [@2022-12-29|MR | MR][@2022-12-29|CT | CT][@guideline:esgo_esmo_esp_consensus_ovariancancer_2024__v00000000 | Page 8].\n\n- Current staging rests on 2022-12-29 CT/MR showing progressive liver and presacral/sacral disease; repeat cross‑sectional imaging before PET if outdated [@2022-12-29|MR | MR][@2022-12-29|CT | CT].\n\n- When performed, PET interpretation should focus on defining true osseous and extrahepatic metastatic burden beyond MRI/CT, to refine radiotherapy targeting [@2022-12-29|MR | MR][@2022-12-29|CT | CT]."}}, "interaction_log": {"Round 1": {"Turn 1": {"chair": {"chair": null, "oncologist": "Before finalizing a non‑platinum regimen, we must correct severe anemia and document ECOG and prior toxicities; otherwise regimen intensity decisions risk excess toxicity [@20230103|5600862 | LAB].", "radiologist": "Please confirm whether any CT/MRI after 2022‑12‑29/30 exist and, if not, whether PET‑CT would realistically change local vs systemic planning [@2022-12-29|MR] [@2022-12-29|CT].", "pathologist": "Kindly clarify in the report whether any features suggest alternative histotype or mixed tumor, as this could alter systemic strategy [@2022-03-28 | CT].", "nuclear": "Given already clear hepatic and bone metastases on CT/MRI, please advise if PET‑CT would add actionable information beyond current staging [@guideline:esgo_esmo_esp_consensus_ovariancancer_2024__v00000000 | Page 8]."}, "oncologist": {"chair": "Before committing to a specific non‑platinum systemic strategy, I need ECOG status, detailed symptom burden, and prior toxicity profile to judge tolerability and dose intensity; anemia work‑up and transfusion plan should be clarified urgently to avoid under‑ or overdosing cytotoxic therapy in the context of Hgb 74 g/L. [@20230103|5600862 | LAB]", "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "radiologist": {"chair": "Imaging facts in the MDT summary (widespread hepatic and pelvic osseous disease) match only the 2022-12-29 CT/MR; please confirm there is no more recent CT/MRI, otherwise updated scans are needed to guide current decisions [@2022-12-29|MR | MR] [@2022-12-29|CT | CT].", "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "pathologist": {"chair": null, "oncologist": "From pathology side, key missing item is a detailed NGS interpretive report classifying the germline ATM p.Y316C variant (pathogenic vs VUS) and commenting on trial eligibility. [@OH2203828 | Genomics]", "radiologist": null, "pathologist": null, "nuclear": null}, "nuclear": {"chair": null, "oncologist": null, "radiologist": "From nuclear perspective, no actual PET report is available; if PET-CT is intended to guide further local measures, please confirm whether any PET has been performed after 2022-12-29 cross-sectional imaging or explicitly schedule one, as current staging relies solely on MRI/CT [@2022-12-29|MR | MR][@2022-12-29|CT | CT].", "pathologist": null, "nuclear": null}}}}, "agent_logs": {"chair": [{"role": "chair", "user_message": "Give INITIAL opinion (use ONLY your system-provided patient facts).\nReturn up to 3 bullets, each ≤20 words.\nIf key data missing, say exactly what needs updating.\nAt least ONE bullet must be evidence-based and include [@guideline:doc_id | Page xx] or [@pubmed | PMID].\nIf you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].\nFor clinical reports, use actual report_id from report data with type: [@actual_report_id | LAB], [@actual_report_id | Genomics], [@actual_report_id | MR], [@actual_report_id | CT] (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy].", "assistant_reply": "- Platinum‑resistant metastatic clear cell ovarian carcinoma with rapid progression in liver, presacral/sacral and bone; systemic non‑platinum regimen indicated [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 10].  \n\n- Baseline anemia (Hgb 74 g/L) requires correction and transfusion/iron assessment before starting further systemic therapy [@20230103|5600862 | LAB].  \n\n- Before firm plan: document ECOG status, pain/skeletal symptoms, prior toxicities, and confirm current MRI/CT images and full NGS interpretation details [@OH2203828 | Genomics].", "timestamp": "2026-01-21T07:01:57.709438"}, {"role": "chair", "user_message": "ROLE: chair. VISIT: 2023-01-03 08:53:29.260000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\n[MDT_GLOBAL_KNOWLEDGE]\nKey Knowledge:\n- Platinum‑resistant recurrent high‑grade clear cell ovarian carcinoma with rapid systemic progression (liver, presacral/sacral, pelvic bone, peritoneal nodules).\n- Rising tumor markers (CA125/CA19‑9) consistent with radiologic progression.\n- Significant anemia (Hgb 74 g/L) requiring correction; renal/hepatic function otherwise acceptable for systemic therapy.\n- Histology/IHC confirm clear cell carcinoma; MMR proficient (no MSI‑H), BRCA1/2 and HRD negative; germline ATM variant of note without clear targetable HRR implication.\n- Current CT/MRI show extensive hepatic and pelvic osseous disease; PET‑CT could further refine whole‑body metastatic burden.\n\nControversies:\n- Optimal choice and intensity of non‑platinum systemic regimen in the context of severe anemia and clear cell histology.\n- Added value and timing of PET‑CT given already advanced disease documented on CT/MRI.\n- Relevance and actionability of germline ATM variant in this clinical context.\n\nMissing Info:\n- ECOG performance status and detailed symptom burden (pain, skeletal symptoms, functional impact).\n- Full toxicity history from prior therapies and current medications.\n- Most recent cross‑sectional imaging dates and formal reports; any interval changes since last CT/MRI.\n- Detailed NGS interpretive report regarding ATM variant classification and potential clinical trial options.\n- Current anemia work‑up (iron studies, B12/folate, hemolysis markers) and transfusion history.\n\nWorking Plan:\n- Optimize anemia before further systemic therapy (transfusion +/- iron/other as indicated) and reassess fitness for treatment.\n- Document ECOG status, pain/skeletal symptoms, and prior treatment toxicities to guide regimen selection.\n- Confirm and review latest CT/MRI; consider PET‑CT for full metastatic mapping if results would alter systemic or palliative local approaches.\n- Discuss non‑platinum systemic options appropriate for platinum‑resistant clear cell histology, tailored to organ function and performance status.\n- Review full NGS report including ATM variant in molecular tumor board context for potential trial eligibility or targeted strategies.\n\nAllowed targets: [oncologist,radiologist,pathologist,nuclear]\n\nEVIDENCE TAGS (if your message references evidence):\n- Any factual statement about past tests/treatments must include [@actual_report_id | LAB/Genomics/MR/CT] using actual report_id from report data (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy]. or say unknown.\n- Any statement derived from guideline or PubMed literature must include [@guideline:doc_id | Page xx] or [@pubmed | PMID].\n- If you cite guideline/PubMed evidence or reference clinical trials, include appropriate tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].\n\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences with evidence tags if applicable>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"yes\",\"messages\":[{\"target\":\"oncologist\",\"message\":\"Before finalizing a non‑platinum regimen, we must correct severe anemia and document ECOG and prior toxicities; otherwise regimen intensity decisions risk excess toxicity [@20230103|5600862 | LAB].\",\"why\":\"safety\"},{\"target\":\"radiologist\",\"message\":\"Please confirm whether any CT/MRI after 2022‑12‑29/30 exist and, if not, whether PET‑CT would realistically change local vs systemic planning [@2022-12-29|MR] [@2022-12-29|CT].\",\"why\":\"missing\"},{\"target\":\"pathologist\",\"message\":\"Kindly clarify in the report whether any features suggest alternative histotype or mixed tumor, as this could alter systemic strategy [@2022-03-28 | CT].\",\"why\":\"missing\"},{\"target\":\"nuclear\",\"message\":\"Given already clear hepatic and bone metastases on CT/MRI, please advise if PET‑CT would add actionable information beyond current staging [@guideline:esgo_esmo_esp_consensus_ovariancancer_2024__v00000000 | Page 8].\",\"why\":\"missing\"}]}", "timestamp": "2026-01-21T07:02:24.351752"}, {"role": "chair", "user_message": "Given MDT context:\n[MDT_GLOBAL_KNOWLEDGE]\nKey Knowledge:\n- Platinum‑resistant recurrent high‑grade clear cell ovarian carcinoma with rapid systemic progression (liver, presacral/sacral, pelvic bone, peritoneal nodules).\n- Rising tumor markers (CA125/CA19‑9) consistent with radiologic progression.\n- Significant anemia (Hgb 74 g/L) requiring correction; renal/hepatic function otherwise acceptable for systemic therapy.\n- Histology/IHC confirm clear cell carcinoma; MMR proficient (no MSI‑H), BRCA1/2 and HRD negative; germline ATM variant of note without clear targetable HRR implication.\n- Current CT/MRI show extensive hepatic and pelvic osseous disease; PET‑CT could further refine whole‑body metastatic burden.\n\nControversies:\n- Optimal choice and intensity of non‑platinum systemic regimen in the context of severe anemia and clear cell histology.\n- Added value and timing of PET‑CT given already advanced disease documented on CT/MRI.\n- Relevance and actionability of germline ATM variant in this clinical context.\n\nMissing Info:\n- ECOG performance status and detailed symptom burden (pain, skeletal symptoms, functional impact).\n- Full toxicity history from prior therapies and current medications.\n- Most recent cross‑sectional imaging dates and formal reports; any interval changes since last CT/MRI.\n- Detailed NGS interpretive report regarding ATM variant classification and potential clinical trial options.\n- Current anemia work‑up (iron studies, B12/folate, hemolysis markers) and transfusion history.\n\nWorking Plan:\n- Optimize anemia before further systemic therapy (transfusion +/- iron/other as indicated) and reassess fitness for treatment.\n- Document ECOG status, pain/skeletal symptoms, and prior treatment toxicities to guide regimen selection.\n- Confirm and review latest CT/MRI; consider PET‑CT for full metastatic mapping if results would alter systemic or palliative local approaches.\n- Discuss non‑platinum systemic options appropriate for platinum‑resistant clear cell histology, tailored to organ function and performance status.\n- Review full NGS report including ATM variant in molecular tumor board context for potential trial eligibility or targeted strategies.\n\n[RECENT_DELTAS]\n[R1T1 DELTA] 2 | LAB] | radiologist->chair(missing): Imaging facts in the MDT summary (widespread hepatic and pelvic osseous disease) match only the 2022-12-29 CT/MR; please confirm there is no more recent CT/MRI, otherwise updated scans are needed to guide current decisions [@2022-12-29|MR | MR] [@2022-12-29|CT | CT]. | pathologist->oncologist(missing): From pathology side, key missing item is a detailed NGS interpretive report classifying the germline ATM p.Y316C variant (pathogenic vs VUS) and commenting on trial eligibility. [@OH2203828 | Genomics] | nuclear->radiologist(missing): From nuclear perspective, no actual PET report is available; if PET-CT is intended to guide further local measures, please confirm whether any PET has been performed after 2022-12-29 cross-sectional imaging or explicitly schedule one, as current staging relies solely on MRI/CT [@2022-12-29|MR | MR][@2022-12-29|CT | CT].\n\nDISCUSSION HISTORY (this round):\nTurn 1: chair→oncologist: Before finalizing a non‑platinum regimen, we must correct severe anemia and document ECOG and prior toxicities; otherwise regimen intensity decisions risk excess toxicity [@20230103|5600862 | LAB]. | chair→radiologist: Please confirm whether any CT/MRI after 2022‑12‑29/30 exist and, if not, whether PET‑CT would realistically change local vs systemic planning [@2022-12-29|MR] [@2022-12-29|CT]. | chair→pathologist: Kindly clarify in the report whether any features suggest alternative histotype or mixed tumor, as this could alter systemic strategy [@2022-03-28 | CT].\n\nProvide FINAL refined plan based on the above context and discussions.\nUp to 3 bullets, each ≤20 words.\nAny factual claim must include [@actual_report_id | LAB/Genomics/MR/CT] using actual report_id from report data (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy]. or say unknown.\nAt least ONE bullet must be evidence-based and include [@guideline:doc_id | Page xx] or [@pubmed | PMID].\nIf you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].\nIf discussions mentioned specific evidence, you may reference it with appropriate tags.", "assistant_reply": "- Correct severe anemia and clarify ECOG, symptom burden, prior toxicities before initiating any non‑platinum systemic therapy [@20230103|5600862 | LAB].  \n\n- Proceed with non‑platinum systemic regimen suitable for platinum‑resistant clear cell disease once optimized, considering trial options and ATM‑related eligibility [@OH2203828 | Genomics][@pubmed | 30109783].  \n\n- Update staging with latest CT/MRI; add PET‑CT only if results would change systemic versus palliative local strategy [@2022-12-29|MR | MR][@2022-12-29|CT | CT][@guideline:esgo_esmo_esp_consensus_ovariancancer_2024__v00000000 | Page 8].", "timestamp": "2026-01-21T07:03:01.105242"}, {"role": "chair", "user_message": "\nAs the MDT chair for gynecologic oncology, you are seeing the patient at OUTPATIENT TIME: 2023-01-03 08:53:29.260000.\nBased on PATIENT FACTS + MDT discussion + FINAL refined plans from all experts, determine the CURRENT best management plan for this visit.\n\n# MDT DISCUSSION SUMMARY\nKey Knowledge:\n- Platinum‑resistant recurrent high‑grade clear cell ovarian carcinoma with rapid systemic progression (liver, presacral/sacral, pelvic bone, peritoneal nodules).\n- Rising CA125/CA19‑9 consistent with radiologic progression.\n- Significant anemia (Hgb 74 g/L) requiring correction; renal/hepatic function acceptable for systemic therapy once optimized.\n- Histology/IHC confirm pure high‑grade ovarian clear cell carcinoma; MMR proficient (MLH1/MSH2/MSH6/PMS2 retained), ER/PR focally expressed; BRCA1/2 and HRD negative; germline ATM p.Y316C variant noted.\n- Current staging is based on 2022‑12‑29 CT/MR showing progressive liver and presacral/sacral disease; PET‑CT not yet performed and considered only if management‑altering.\n\nControversies:\n- Optimal non‑platinum relapse regimen and intensity for platinum‑resistant clear cell histology in the setting of severe baseline anemia.\n- Threshold for ordering PET‑CT versus repeating CT/MR alone, and whether PET findings would realistically change systemic versus palliative local strategies.\n- Clinical actionability and trial relevance of the germline ATM variant in this patient’s context.\n\nMissing Info:\n- ECOG performance status and detailed symptom burden (pain, skeletal, neurologic, functional impact).\n- Full prior treatment toxicity history and current medications.\n- Confirmation that no post‑2022‑12‑29 CT/MRI exists; need for updated cross‑sectional imaging if disease status is uncertain.\n- Integrated NGS/molecular addendum summarizing HRD‑negative, BRCA‑wild‑type status and detailed classification/implications of ATM p.Y316C.\n- Current anemia work‑up (iron/B12/folate, hemolysis markers) and transfusion/iron replacement history.\n\nWorking Plan:\n- Correct severe anemia and complete anemia work‑up; then reassess suitability for full‑dose non‑platinum systemic therapy.\n- Document ECOG, symptom burden (including bone/neurologic symptoms), and prior toxicities to individualize relapse systemic regimen and supportive care.\n- Confirm absence of more recent imaging; update staging with new CT/MR if prior (2022‑12‑29) set is outdated or discordant with current symptoms.\n- Consider FDG PET‑CT only if additional disease mapping would change systemic regimen choice, clinical trial eligibility, or local palliative interventions (e.g., radiotherapy targeting).\n- Finalize pathology/molecular documentation: issue addendum confirming pure clear cell histology, MMR proficiency, ER/PR status, and integrated summary of HRD‑negative, BRCA‑wild‑type, and ATM variant, to support systemic and trial planning.\n\n# INITIAL EXPERT OPINIONS\n- chair: - Platinum‑resistant metastatic clear cell ovarian carcinoma with rapid progression in liver, presacral/sacral and bone; systemic non‑platinum regimen indicated [@guideline:esmo_cpg_epithelialovarian_\n- oncologist: - Platinum-resistant recurrent clear cell ovarian carcinoma with rising CA125/CA19-9 and new liver/bone metastases; systemic relapse-therapy category indicated. [@20221229|9703212 | LAB] [@guideline:e\n- radiologist: - Progressive presacral pelvic mass with sacral and right iliac bone involvement; multiple stable pelvic mesenteric/peritoneal nodules suspicious for metastases [@2022-10-24|MR | MR] [@2022-12-29|MR |\n- pathologist: - Morphology and IHC strongly support recurrent ovarian clear cell carcinoma involving rectosigmoid, retroperitoneum, and vagina, high‑grade. [@guideline:esgo_esmo_esp_consensus_ovariancancer_2024__v0\n- nuclear: - Known pelvic presacral mass with sacral and right iliac bone involvement; PET could better define osseous/metastatic extent and activity [@2022-12-29|MR | MR].\n\n- Progressive multifocal hepatic meta\n\n# DISCUSSION INTERACTIONS\nRound 1: R1T1: chair→oncologist: Before finalizing a non‑platinum regimen, we must correct severe anemia and document ECOG and prior  | R1T1: chair→radiologist: Please confirm whether any CT/MRI after 2022‑12‑29/30 exist and, if not, whether PET‑CT would realis | R1T1: chair→pathologist: Kindly clarify in the report whether any features suggest alternative histotype or mixed tumor, as t | R1T1: chair→nuclear: Given already clear hepatic and bone metastases on CT/MRI, please advise if PET‑CT would add actiona | R1T1: oncologist→chair: Before committing to a specific non‑platinum systemic strategy, I need ECOG status, detailed symptom\n\n\n\n# FINAL REFINED PLANS (All experts, all rounds)\n{\n  \"Round 1\": {\n    \"chair\": \"- Correct severe anemia and clarify ECOG, symptom burden, prior toxicities before initiating any non‑platinum systemic therapy [@20230103|5600862 | LAB].  \\n\\n- Proceed with non‑platinum systemic regimen suitable for platinum‑resistant clear cell disease once optimized, considering trial options and ATM‑related eligibility [@OH2203828 | Genomics][@pubmed | 30109783].  \\n\\n- Update staging with latest CT/MRI; add PET‑CT only if results would change systemic versus palliative local strategy [@2022-12-29|MR | MR][@2022-12-29|CT | CT][@guideline:esgo_esmo_esp_consensus_ovariancancer_2024__v00000000 | Page 8].\",\n    \"oncologist\": \"- Correct anemia and document ECOG, symptom burden, and prior toxicities before initiating individualized non‑platinum relapse systemic therapy. [@20230103|5600862 | LAB] [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 10]  \\n\\n- Proceed with systemic relapse‑therapy planning assuming clear cell histology, MMR proficiency, BRCA/HRD negativity, and germline ATM variant per NGS. [@OH2203828 | Genomics] [@pubmed | 30109783]  \\n\\n- Confirm no post‑2022‑12‑29 CT/MRI; order PET‑CT only if results would modify systemic choice or local palliative interventions. [@2022-12-29|MR | MR] [@2022-12-29|CT | CT]\",\n    \"radiologist\": \"- No cross‑sectional imaging is available after 2022‑12‑29; current staging relies on that CT/MR set [@2022-12-29|MR | MR] [@2022-12-29|CT | CT].  \\n\\n- Before PET‑CT, clarify whether updated CT/MR is planned; PET should be reserved for scenarios where it may alter management [@guideline:esgo_esmo_esp_consensus_ovariancancer_2024__v00000000 | Page 8].  \\n\\n- Document any new focal bone or neurologic symptoms to prioritize targeted imaging (e.g., spine/pelvis MRI) if clinically indicated [@2022-12-29|MR | MR].\",\n    \"pathologist\": \"- Confirm final histology as pure high‑grade ovarian clear cell carcinoma; no morphologic evidence of mixed or alternative histotype. [@guideline:esgo_esmo_esp_consensus_ovariancancer_2024__v00000000 | Page 6]\\n\\n- Clearly state MMR proficiency (MLH1/MSH2/MSH6/PMS2 retained) and ER/PR focal expression in the pathology addendum. [@2022-03-28 | LAB]\\n\\n- Request integrated molecular addendum summarizing HRD‑negative, BRCA‑wild‑type status and detailing germline ATM p.Y316C classification/implications. [@OH2203828 | Genomics]\",\n    \"nuclear\": \"- No PET-CT yet; recommend whole‑body FDG PET-CT only if updated mapping would alter local palliation or systemic strategy [@2022-12-29|MR | MR][@2022-12-29|CT | CT][@guideline:esgo_esmo_esp_consensus_ovariancancer_2024__v00000000 | Page 8].\\n\\n- Current staging rests on 2022-12-29 CT/MR showing progressive liver and presacral/sacral disease; repeat cross‑sectional imaging before PET if outdated [@2022-12-29|MR | MR][@2022-12-29|CT | CT].\\n\\n- When performed, PET interpretation should focus on defining true osseous and extrahepatic metastatic burden beyond MRI/CT, to refine radiotherapy targeting [@2022-12-29|MR | MR][@2022-12-29|CT | CT].\"\n  }\n}\n\n# CLINICAL TRIAL RECOMMENDATION (from assistant)\nTrial Recommendation:\n- id: 350\n- name: 评价注射用BL-B01D1在复发或转移性妇科恶性肿瘤等多种实体瘤患者中的安全性、耐受性、药代动力学及有效性的Ib/II期临床研究\n- Reason: Recurrent metastatic ovarian clear cell carcinoma is a gynecologic malignancy after ≥1 prior standard therapy, matching this 2L–3L gynecologic trial without biomarker requirements.\n- Missing eligibility confirmations (0-2 items):\n  - Confirmation of ECOG performance status and other general organ function criteria\n  - Confirmation that there is no other available standard systemic therapy deemed appropriate by treating physician\n\nSTRICT RULES:\n- Any factual statement about past tests/treatments must include [@actual_report_id | LAB/Genomics/MR/CT] using actual report_id from report data (e.g., [@20220407|17300673 | LAB], [@OH2203828|2022-04-18 | Genomics], [@2022-12-29 | MR], [@2022-12-29 | CT]). Note: Always use spaces around | for consistency: [@xxx | yyy]. or say unknown.\n- Any statement derived from guideline or PubMed literature must include [@guideline:doc_id | Page xx] or [@pubmed | PMID].\n- If you cite guideline/PubMed evidence in Core Treatment Strategy or Change Triggers, include at least one tag in that bullet.\n- If a clinical trial has been recommended by the assistant and you judge it appropriate for the patient, mention it naturally within Core Treatment Strategy or Change Triggers and cite it using [@trial | trial_id] format (e.g., [@trial | 350]).\n- If experts disagree, pick the safest plan and state the key uncertainty.\n- You MUST consider the MDT discussion summary and interactions above when making your decision.\n\n# Response Format\nFinal Assessment:\n<1–3 sentences: summarize histology/biology, current disease status, and key uncertainties>\n\nCore Treatment Strategy:\n- < ≤20 words concrete decision >\n- < ≤20 words concrete decision >\n- < ≤20 words concrete decision >\n- < ≤20 words concrete decision >\n\nChange Triggers:\n- < ≤20 words \"if X, then adjust management from A to B\" >\n- < ≤20 words \"if X, then adjust management from A to B\" >\n", "assistant_reply": "Final Assessment:\nHigh‑grade ovarian clear cell carcinoma, platinum‑resistant, with progressive hepatic and presacral/sacral/iliac bone metastases and severe anemia; main uncertainties are performance status, anemia etiology, and trial options.\n\nCore Treatment Strategy:\n- Immediately investigate and correct anemia (iron/B12/folate, hemolysis, transfusion as needed) before further systemic therapy [@20230103|5600862 | LAB].  \n- Document ECOG status, pain (including bone/neurologic), and prior toxicity to define feasible non‑platinum relapse‑therapy intensity [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 10].  \n- Plan non‑platinum systemic relapse therapy for platinum‑resistant clear cell disease once optimized; parallelly screen for eligible phase Ib/II trials [@OH2203828 | Genomics][@pubmed | 30109783][@trial | 350].  \n- Use 2022‑12‑29 CT/MR as staging baseline; repeat CT/MR if clinical status changes, reserving PET‑CT only if results would alter systemic or palliative local strategies [@2022-12-29|MR | MR][@2022-12-29|CT | CT][@guideline:esgo_esmo_esp_consensus_ovariancancer_2024__v00000000 | Page 8].  \n\nChange Triggers:\n- If anemia persists or worsens despite work‑up/treatment, delay or de‑escalate systemic therapy intensity and prioritize supportive measures.  \n- If new focal bone/neurologic symptoms or rapid marker rise occur, obtain urgent targeted imaging and consider palliative radiotherapy or adjusted systemic approach.", "timestamp": "2026-01-21T07:03:43.285660"}], "oncologist": [{"role": "oncologist", "user_message": "Give INITIAL opinion (use ONLY your system-provided patient facts).\nReturn up to 3 bullets, each ≤20 words.\nIf key data missing, say exactly what needs updating.\nAt least ONE bullet must be evidence-based and include [@guideline:doc_id | Page xx] or [@pubmed | PMID].\nIf you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].\nFor clinical reports, use actual report_id from report data with type: [@actual_report_id | LAB], [@actual_report_id | Genomics], [@actual_report_id | MR], [@actual_report_id | CT] (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy].", "assistant_reply": "- Platinum-resistant recurrent clear cell ovarian carcinoma with rising CA125/CA19-9 and new liver/bone metastases; systemic relapse-therapy category indicated. [@20221229|9703212 | LAB] [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 10]  \n\n- Significant anemia (Hgb 74 g/L) may limit intensity of cytotoxic systemic therapy; requires optimization/transfusion before full-dose treatment. [@20230103|5600862 | LAB]  \n\n- Organ function (renal/hepatic) appears acceptable for most systemic options; confirm current performance status and recent cross-sectional imaging details for planning. [@20221229|8300002 | LAB]", "timestamp": "2026-01-21T07:02:00.409643"}, {"role": "oncologist", "user_message": "ROLE: oncologist. VISIT: 2023-01-03 08:53:29.260000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\n[MDT_GLOBAL_KNOWLEDGE]\nKey Knowledge:\n- Platinum‑resistant recurrent high‑grade clear cell ovarian carcinoma with rapid systemic progression (liver, presacral/sacral, pelvic bone, peritoneal nodules).\n- Rising tumor markers (CA125/CA19‑9) consistent with radiologic progression.\n- Significant anemia (Hgb 74 g/L) requiring correction; renal/hepatic function otherwise acceptable for systemic therapy.\n- Histology/IHC confirm clear cell carcinoma; MMR proficient (no MSI‑H), BRCA1/2 and HRD negative; germline ATM variant of note without clear targetable HRR implication.\n- Current CT/MRI show extensive hepatic and pelvic osseous disease; PET‑CT could further refine whole‑body metastatic burden.\n\nControversies:\n- Optimal choice and intensity of non‑platinum systemic regimen in the context of severe anemia and clear cell histology.\n- Added value and timing of PET‑CT given already advanced disease documented on CT/MRI.\n- Relevance and actionability of germline ATM variant in this clinical context.\n\nMissing Info:\n- ECOG performance status and detailed symptom burden (pain, skeletal symptoms, functional impact).\n- Full toxicity history from prior therapies and current medications.\n- Most recent cross‑sectional imaging dates and formal reports; any interval changes since last CT/MRI.\n- Detailed NGS interpretive report regarding ATM variant classification and potential clinical trial options.\n- Current anemia work‑up (iron studies, B12/folate, hemolysis markers) and transfusion history.\n\nWorking Plan:\n- Optimize anemia before further systemic therapy (transfusion +/- iron/other as indicated) and reassess fitness for treatment.\n- Document ECOG status, pain/skeletal symptoms, and prior treatment toxicities to guide regimen selection.\n- Confirm and review latest CT/MRI; consider PET‑CT for full metastatic mapping if results would alter systemic or palliative local approaches.\n- Discuss non‑platinum systemic options appropriate for platinum‑resistant clear cell histology, tailored to organ function and performance status.\n- Review full NGS report including ATM variant in molecular tumor board context for potential trial eligibility or targeted strategies.\n\nAllowed targets: [chair,radiologist,pathologist,nuclear]\n\nEVIDENCE TAGS (if your message references evidence):\n- Any factual statement about past tests/treatments must include [@actual_report_id | LAB/Genomics/MR/CT] using actual report_id from report data (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy]. or say unknown.\n- Any statement derived from guideline or PubMed literature must include [@guideline:doc_id | Page xx] or [@pubmed | PMID].\n- If you cite guideline/PubMed evidence or reference clinical trials, include appropriate tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].\n\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences with evidence tags if applicable>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"yes\",\"messages\":[{\"target\":\"chair\",\"message\":\"Before committing to a specific non‑platinum systemic strategy, I need ECOG status, detailed symptom burden, and prior toxicity profile to judge tolerability and dose intensity; anemia work‑up and transfusion plan should be clarified urgently to avoid under‑ or overdosing cytotoxic therapy in the context of Hgb 74 g/L. [@20230103|5600862 | LAB]\",\"why\":\"missing\"}]}", "timestamp": "2026-01-21T07:02:26.816587"}, {"role": "oncologist", "user_message": "Given MDT context:\n[MDT_GLOBAL_KNOWLEDGE]\nKey Knowledge:\n- Platinum‑resistant recurrent high‑grade clear cell ovarian carcinoma with rapid systemic progression (liver, presacral/sacral, pelvic bone, peritoneal nodules).\n- Rising tumor markers (CA125/CA19‑9) consistent with radiologic progression.\n- Significant anemia (Hgb 74 g/L) requiring correction; renal/hepatic function otherwise acceptable for systemic therapy.\n- Histology/IHC confirm clear cell carcinoma; MMR proficient (no MSI‑H), BRCA1/2 and HRD negative; germline ATM variant of note without clear targetable HRR implication.\n- Current CT/MRI show extensive hepatic and pelvic osseous disease; PET‑CT could further refine whole‑body metastatic burden.\n\nControversies:\n- Optimal choice and intensity of non‑platinum systemic regimen in the context of severe anemia and clear cell histology.\n- Added value and timing of PET‑CT given already advanced disease documented on CT/MRI.\n- Relevance and actionability of germline ATM variant in this clinical context.\n\nMissing Info:\n- ECOG performance status and detailed symptom burden (pain, skeletal symptoms, functional impact).\n- Full toxicity history from prior therapies and current medications.\n- Most recent cross‑sectional imaging dates and formal reports; any interval changes since last CT/MRI.\n- Detailed NGS interpretive report regarding ATM variant classification and potential clinical trial options.\n- Current anemia work‑up (iron studies, B12/folate, hemolysis markers) and transfusion history.\n\nWorking Plan:\n- Optimize anemia before further systemic therapy (transfusion +/- iron/other as indicated) and reassess fitness for treatment.\n- Document ECOG status, pain/skeletal symptoms, and prior treatment toxicities to guide regimen selection.\n- Confirm and review latest CT/MRI; consider PET‑CT for full metastatic mapping if results would alter systemic or palliative local approaches.\n- Discuss non‑platinum systemic options appropriate for platinum‑resistant clear cell histology, tailored to organ function and performance status.\n- Review full NGS report including ATM variant in molecular tumor board context for potential trial eligibility or targeted strategies.\n\n[RECENT_DELTAS]\n[R1T1 DELTA] 2 | LAB] | radiologist->chair(missing): Imaging facts in the MDT summary (widespread hepatic and pelvic osseous disease) match only the 2022-12-29 CT/MR; please confirm there is no more recent CT/MRI, otherwise updated scans are needed to guide current decisions [@2022-12-29|MR | MR] [@2022-12-29|CT | CT]. | pathologist->oncologist(missing): From pathology side, key missing item is a detailed NGS interpretive report classifying the germline ATM p.Y316C variant (pathogenic vs VUS) and commenting on trial eligibility. [@OH2203828 | Genomics] | nuclear->radiologist(missing): From nuclear perspective, no actual PET report is available; if PET-CT is intended to guide further local measures, please confirm whether any PET has been performed after 2022-12-29 cross-sectional imaging or explicitly schedule one, as current staging relies solely on MRI/CT [@2022-12-29|MR | MR][@2022-12-29|CT | CT].\n\nDISCUSSION HISTORY (this round):\nTurn 1: chair→oncologist: Before finalizing a non‑platinum regimen, we must correct severe anemia and document ECOG and prior toxicities; otherwise regimen intensity decisions risk excess toxicity [@20230103|5600862 | LAB]. | chair→radiologist: Please confirm whether any CT/MRI after 2022‑12‑29/30 exist and, if not, whether PET‑CT would realistically change local vs systemic planning [@2022-12-29|MR] [@2022-12-29|CT]. | chair→pathologist: Kindly clarify in the report whether any features suggest alternative histotype or mixed tumor, as this could alter systemic strategy [@2022-03-28 | CT].\n\nProvide FINAL refined plan based on the above context and discussions.\nUp to 3 bullets, each ≤20 words.\nAny factual claim must include [@actual_report_id | LAB/Genomics/MR/CT] using actual report_id from report data (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy]. or say unknown.\nAt least ONE bullet must be evidence-based and include [@guideline:doc_id | Page xx] or [@pubmed | PMID].\nIf you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].\nIf discussions mentioned specific evidence, you may reference it with appropriate tags.", "assistant_reply": "- Correct anemia and document ECOG, symptom burden, and prior toxicities before initiating individualized non‑platinum relapse systemic therapy. [@20230103|5600862 | LAB] [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 10]  \n\n- Proceed with systemic relapse‑therapy planning assuming clear cell histology, MMR proficiency, BRCA/HRD negativity, and germline ATM variant per NGS. [@OH2203828 | Genomics] [@pubmed | 30109783]  \n\n- Confirm no post‑2022‑12‑29 CT/MRI; order PET‑CT only if results would modify systemic choice or local palliative interventions. [@2022-12-29|MR | MR] [@2022-12-29|CT | CT]", "timestamp": "2026-01-21T07:03:05.001960"}], "radiologist": [{"role": "radiologist", "user_message": "Give INITIAL opinion (use ONLY your system-provided patient facts).\nReturn up to 3 bullets, each ≤20 words.\nIf key data missing, say exactly what needs updating.\nAt least ONE bullet must be evidence-based and include [@guideline:doc_id | Page xx] or [@pubmed | PMID].\nIf you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].\nFor clinical reports, use actual report_id from report data with type: [@actual_report_id | LAB], [@actual_report_id | Genomics], [@actual_report_id | MR], [@actual_report_id | CT] (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy].", "assistant_reply": "- Progressive presacral pelvic mass with sacral and right iliac bone involvement; multiple stable pelvic mesenteric/peritoneal nodules suspicious for metastases [@2022-10-24|MR | MR] [@2022-12-29|MR | MR].  \n\n- Liver: multiple metastatic nodules increasing in number and size; spleen with patchy low‑density area possibly infarct, needs clinical correlation [@2022-12-29|CT | CT].  \n\n- Cross‑sectional CT/MRI adequately demonstrate advanced, recurrent disease distribution for MDT treatment planning [@guideline:esgo_esmo_esp_consensus_ovariancancer_2024__v00000000 | Page 8].", "timestamp": "2026-01-21T07:02:02.651132"}, {"role": "radiologist", "user_message": "ROLE: radiologist. VISIT: 2023-01-03 08:53:29.260000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\n[MDT_GLOBAL_KNOWLEDGE]\nKey Knowledge:\n- Platinum‑resistant recurrent high‑grade clear cell ovarian carcinoma with rapid systemic progression (liver, presacral/sacral, pelvic bone, peritoneal nodules).\n- Rising tumor markers (CA125/CA19‑9) consistent with radiologic progression.\n- Significant anemia (Hgb 74 g/L) requiring correction; renal/hepatic function otherwise acceptable for systemic therapy.\n- Histology/IHC confirm clear cell carcinoma; MMR proficient (no MSI‑H), BRCA1/2 and HRD negative; germline ATM variant of note without clear targetable HRR implication.\n- Current CT/MRI show extensive hepatic and pelvic osseous disease; PET‑CT could further refine whole‑body metastatic burden.\n\nControversies:\n- Optimal choice and intensity of non‑platinum systemic regimen in the context of severe anemia and clear cell histology.\n- Added value and timing of PET‑CT given already advanced disease documented on CT/MRI.\n- Relevance and actionability of germline ATM variant in this clinical context.\n\nMissing Info:\n- ECOG performance status and detailed symptom burden (pain, skeletal symptoms, functional impact).\n- Full toxicity history from prior therapies and current medications.\n- Most recent cross‑sectional imaging dates and formal reports; any interval changes since last CT/MRI.\n- Detailed NGS interpretive report regarding ATM variant classification and potential clinical trial options.\n- Current anemia work‑up (iron studies, B12/folate, hemolysis markers) and transfusion history.\n\nWorking Plan:\n- Optimize anemia before further systemic therapy (transfusion +/- iron/other as indicated) and reassess fitness for treatment.\n- Document ECOG status, pain/skeletal symptoms, and prior treatment toxicities to guide regimen selection.\n- Confirm and review latest CT/MRI; consider PET‑CT for full metastatic mapping if results would alter systemic or palliative local approaches.\n- Discuss non‑platinum systemic options appropriate for platinum‑resistant clear cell histology, tailored to organ function and performance status.\n- Review full NGS report including ATM variant in molecular tumor board context for potential trial eligibility or targeted strategies.\n\nAllowed targets: [chair,oncologist,pathologist,nuclear]\n\nEVIDENCE TAGS (if your message references evidence):\n- Any factual statement about past tests/treatments must include [@actual_report_id | LAB/Genomics/MR/CT] using actual report_id from report data (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy]. or say unknown.\n- Any statement derived from guideline or PubMed literature must include [@guideline:doc_id | Page xx] or [@pubmed | PMID].\n- If you cite guideline/PubMed evidence or reference clinical trials, include appropriate tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].\n\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences with evidence tags if applicable>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"yes\",\"messages\":[{\"target\":\"chair\",\"message\":\"Imaging facts in the MDT summary (widespread hepatic and pelvic osseous disease) match only the 2022-12-29 CT/MR; please confirm there is no more recent CT/MRI, otherwise updated scans are needed to guide current decisions [@2022-12-29|MR | MR] [@2022-12-29|CT | CT].\",\"why\":\"missing\"}]}", "timestamp": "2026-01-21T07:02:30.113105"}, {"role": "radiologist", "user_message": "Given MDT context:\n[MDT_GLOBAL_KNOWLEDGE]\nKey Knowledge:\n- Platinum‑resistant recurrent high‑grade clear cell ovarian carcinoma with rapid systemic progression (liver, presacral/sacral, pelvic bone, peritoneal nodules).\n- Rising tumor markers (CA125/CA19‑9) consistent with radiologic progression.\n- Significant anemia (Hgb 74 g/L) requiring correction; renal/hepatic function otherwise acceptable for systemic therapy.\n- Histology/IHC confirm clear cell carcinoma; MMR proficient (no MSI‑H), BRCA1/2 and HRD negative; germline ATM variant of note without clear targetable HRR implication.\n- Current CT/MRI show extensive hepatic and pelvic osseous disease; PET‑CT could further refine whole‑body metastatic burden.\n\nControversies:\n- Optimal choice and intensity of non‑platinum systemic regimen in the context of severe anemia and clear cell histology.\n- Added value and timing of PET‑CT given already advanced disease documented on CT/MRI.\n- Relevance and actionability of germline ATM variant in this clinical context.\n\nMissing Info:\n- ECOG performance status and detailed symptom burden (pain, skeletal symptoms, functional impact).\n- Full toxicity history from prior therapies and current medications.\n- Most recent cross‑sectional imaging dates and formal reports; any interval changes since last CT/MRI.\n- Detailed NGS interpretive report regarding ATM variant classification and potential clinical trial options.\n- Current anemia work‑up (iron studies, B12/folate, hemolysis markers) and transfusion history.\n\nWorking Plan:\n- Optimize anemia before further systemic therapy (transfusion +/- iron/other as indicated) and reassess fitness for treatment.\n- Document ECOG status, pain/skeletal symptoms, and prior treatment toxicities to guide regimen selection.\n- Confirm and review latest CT/MRI; consider PET‑CT for full metastatic mapping if results would alter systemic or palliative local approaches.\n- Discuss non‑platinum systemic options appropriate for platinum‑resistant clear cell histology, tailored to organ function and performance status.\n- Review full NGS report including ATM variant in molecular tumor board context for potential trial eligibility or targeted strategies.\n\n[RECENT_DELTAS]\n[R1T1 DELTA] 2 | LAB] | radiologist->chair(missing): Imaging facts in the MDT summary (widespread hepatic and pelvic osseous disease) match only the 2022-12-29 CT/MR; please confirm there is no more recent CT/MRI, otherwise updated scans are needed to guide current decisions [@2022-12-29|MR | MR] [@2022-12-29|CT | CT]. | pathologist->oncologist(missing): From pathology side, key missing item is a detailed NGS interpretive report classifying the germline ATM p.Y316C variant (pathogenic vs VUS) and commenting on trial eligibility. [@OH2203828 | Genomics] | nuclear->radiologist(missing): From nuclear perspective, no actual PET report is available; if PET-CT is intended to guide further local measures, please confirm whether any PET has been performed after 2022-12-29 cross-sectional imaging or explicitly schedule one, as current staging relies solely on MRI/CT [@2022-12-29|MR | MR][@2022-12-29|CT | CT].\n\nDISCUSSION HISTORY (this round):\nTurn 1: chair→oncologist: Before finalizing a non‑platinum regimen, we must correct severe anemia and document ECOG and prior toxicities; otherwise regimen intensity decisions risk excess toxicity [@20230103|5600862 | LAB]. | chair→radiologist: Please confirm whether any CT/MRI after 2022‑12‑29/30 exist and, if not, whether PET‑CT would realistically change local vs systemic planning [@2022-12-29|MR] [@2022-12-29|CT]. | chair→pathologist: Kindly clarify in the report whether any features suggest alternative histotype or mixed tumor, as this could alter systemic strategy [@2022-03-28 | CT].\n\nProvide FINAL refined plan based on the above context and discussions.\nUp to 3 bullets, each ≤20 words.\nAny factual claim must include [@actual_report_id | LAB/Genomics/MR/CT] using actual report_id from report data (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy]. or say unknown.\nAt least ONE bullet must be evidence-based and include [@guideline:doc_id | Page xx] or [@pubmed | PMID].\nIf you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].\nIf discussions mentioned specific evidence, you may reference it with appropriate tags.", "assistant_reply": "- No cross‑sectional imaging is available after 2022‑12‑29; current staging relies on that CT/MR set [@2022-12-29|MR | MR] [@2022-12-29|CT | CT].  \n\n- Before PET‑CT, clarify whether updated CT/MR is planned; PET should be reserved for scenarios where it may alter management [@guideline:esgo_esmo_esp_consensus_ovariancancer_2024__v00000000 | Page 8].  \n\n- Document any new focal bone or neurologic symptoms to prioritize targeted imaging (e.g., spine/pelvis MRI) if clinically indicated [@2022-12-29|MR | MR].", "timestamp": "2026-01-21T07:03:07.725005"}], "pathologist": [{"role": "pathologist", "user_message": "Give INITIAL opinion (use ONLY your system-provided patient facts).\nReturn up to 3 bullets, each ≤20 words.\nIf key data missing, say exactly what needs updating.\nAt least ONE bullet must be evidence-based and include [@guideline:doc_id | Page xx] or [@pubmed | PMID].\nIf you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].\nFor clinical reports, use actual report_id from report data with type: [@actual_report_id | LAB], [@actual_report_id | Genomics], [@actual_report_id | MR], [@actual_report_id | CT] (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy].", "assistant_reply": "- Morphology and IHC strongly support recurrent ovarian clear cell carcinoma involving rectosigmoid, retroperitoneum, and vagina, high‑grade. [@guideline:esgo_esmo_esp_consensus_ovariancancer_2024__v00000000 | Page 6]\n\n- MMR proteins intact; no evidence of MMR deficiency/MSI‑H on IHC. [@2022-03-28 | LAB]\n\n- Comprehensive NGS: germline ATM p.Y316C; BRCA1/2 and HRD negative; no other pathogenic HRR variants detected. [@OH2203828 | Genomics]", "timestamp": "2026-01-21T07:02:05.922662"}, {"role": "pathologist", "user_message": "ROLE: pathologist. VISIT: 2023-01-03 08:53:29.260000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\n[MDT_GLOBAL_KNOWLEDGE]\nKey Knowledge:\n- Platinum‑resistant recurrent high‑grade clear cell ovarian carcinoma with rapid systemic progression (liver, presacral/sacral, pelvic bone, peritoneal nodules).\n- Rising tumor markers (CA125/CA19‑9) consistent with radiologic progression.\n- Significant anemia (Hgb 74 g/L) requiring correction; renal/hepatic function otherwise acceptable for systemic therapy.\n- Histology/IHC confirm clear cell carcinoma; MMR proficient (no MSI‑H), BRCA1/2 and HRD negative; germline ATM variant of note without clear targetable HRR implication.\n- Current CT/MRI show extensive hepatic and pelvic osseous disease; PET‑CT could further refine whole‑body metastatic burden.\n\nControversies:\n- Optimal choice and intensity of non‑platinum systemic regimen in the context of severe anemia and clear cell histology.\n- Added value and timing of PET‑CT given already advanced disease documented on CT/MRI.\n- Relevance and actionability of germline ATM variant in this clinical context.\n\nMissing Info:\n- ECOG performance status and detailed symptom burden (pain, skeletal symptoms, functional impact).\n- Full toxicity history from prior therapies and current medications.\n- Most recent cross‑sectional imaging dates and formal reports; any interval changes since last CT/MRI.\n- Detailed NGS interpretive report regarding ATM variant classification and potential clinical trial options.\n- Current anemia work‑up (iron studies, B12/folate, hemolysis markers) and transfusion history.\n\nWorking Plan:\n- Optimize anemia before further systemic therapy (transfusion +/- iron/other as indicated) and reassess fitness for treatment.\n- Document ECOG status, pain/skeletal symptoms, and prior treatment toxicities to guide regimen selection.\n- Confirm and review latest CT/MRI; consider PET‑CT for full metastatic mapping if results would alter systemic or palliative local approaches.\n- Discuss non‑platinum systemic options appropriate for platinum‑resistant clear cell histology, tailored to organ function and performance status.\n- Review full NGS report including ATM variant in molecular tumor board context for potential trial eligibility or targeted strategies.\n\nAllowed targets: [chair,oncologist,radiologist,nuclear]\n\nEVIDENCE TAGS (if your message references evidence):\n- Any factual statement about past tests/treatments must include [@actual_report_id | LAB/Genomics/MR/CT] using actual report_id from report data (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy]. or say unknown.\n- Any statement derived from guideline or PubMed literature must include [@guideline:doc_id | Page xx] or [@pubmed | PMID].\n- If you cite guideline/PubMed evidence or reference clinical trials, include appropriate tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].\n\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences with evidence tags if applicable>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"yes\",\"messages\":[{\"target\":\"oncologist\",\"message\":\"From pathology side, key missing item is a detailed NGS interpretive report classifying the germline ATM p.Y316C variant (pathogenic vs VUS) and commenting on trial eligibility. [@OH2203828 | Genomics]\",\"why\":\"missing\"}]}", "timestamp": "2026-01-21T07:02:36.447699"}, {"role": "pathologist", "user_message": "Given MDT context:\n[MDT_GLOBAL_KNOWLEDGE]\nKey Knowledge:\n- Platinum‑resistant recurrent high‑grade clear cell ovarian carcinoma with rapid systemic progression (liver, presacral/sacral, pelvic bone, peritoneal nodules).\n- Rising tumor markers (CA125/CA19‑9) consistent with radiologic progression.\n- Significant anemia (Hgb 74 g/L) requiring correction; renal/hepatic function otherwise acceptable for systemic therapy.\n- Histology/IHC confirm clear cell carcinoma; MMR proficient (no MSI‑H), BRCA1/2 and HRD negative; germline ATM variant of note without clear targetable HRR implication.\n- Current CT/MRI show extensive hepatic and pelvic osseous disease; PET‑CT could further refine whole‑body metastatic burden.\n\nControversies:\n- Optimal choice and intensity of non‑platinum systemic regimen in the context of severe anemia and clear cell histology.\n- Added value and timing of PET‑CT given already advanced disease documented on CT/MRI.\n- Relevance and actionability of germline ATM variant in this clinical context.\n\nMissing Info:\n- ECOG performance status and detailed symptom burden (pain, skeletal symptoms, functional impact).\n- Full toxicity history from prior therapies and current medications.\n- Most recent cross‑sectional imaging dates and formal reports; any interval changes since last CT/MRI.\n- Detailed NGS interpretive report regarding ATM variant classification and potential clinical trial options.\n- Current anemia work‑up (iron studies, B12/folate, hemolysis markers) and transfusion history.\n\nWorking Plan:\n- Optimize anemia before further systemic therapy (transfusion +/- iron/other as indicated) and reassess fitness for treatment.\n- Document ECOG status, pain/skeletal symptoms, and prior treatment toxicities to guide regimen selection.\n- Confirm and review latest CT/MRI; consider PET‑CT for full metastatic mapping if results would alter systemic or palliative local approaches.\n- Discuss non‑platinum systemic options appropriate for platinum‑resistant clear cell histology, tailored to organ function and performance status.\n- Review full NGS report including ATM variant in molecular tumor board context for potential trial eligibility or targeted strategies.\n\n[RECENT_DELTAS]\n[R1T1 DELTA] 2 | LAB] | radiologist->chair(missing): Imaging facts in the MDT summary (widespread hepatic and pelvic osseous disease) match only the 2022-12-29 CT/MR; please confirm there is no more recent CT/MRI, otherwise updated scans are needed to guide current decisions [@2022-12-29|MR | MR] [@2022-12-29|CT | CT]. | pathologist->oncologist(missing): From pathology side, key missing item is a detailed NGS interpretive report classifying the germline ATM p.Y316C variant (pathogenic vs VUS) and commenting on trial eligibility. [@OH2203828 | Genomics] | nuclear->radiologist(missing): From nuclear perspective, no actual PET report is available; if PET-CT is intended to guide further local measures, please confirm whether any PET has been performed after 2022-12-29 cross-sectional imaging or explicitly schedule one, as current staging relies solely on MRI/CT [@2022-12-29|MR | MR][@2022-12-29|CT | CT].\n\nDISCUSSION HISTORY (this round):\nTurn 1: chair→oncologist: Before finalizing a non‑platinum regimen, we must correct severe anemia and document ECOG and prior toxicities; otherwise regimen intensity decisions risk excess toxicity [@20230103|5600862 | LAB]. | chair→radiologist: Please confirm whether any CT/MRI after 2022‑12‑29/30 exist and, if not, whether PET‑CT would realistically change local vs systemic planning [@2022-12-29|MR] [@2022-12-29|CT]. | chair→pathologist: Kindly clarify in the report whether any features suggest alternative histotype or mixed tumor, as this could alter systemic strategy [@2022-03-28 | CT].\n\nProvide FINAL refined plan based on the above context and discussions.\nUp to 3 bullets, each ≤20 words.\nAny factual claim must include [@actual_report_id | LAB/Genomics/MR/CT] using actual report_id from report data (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy]. or say unknown.\nAt least ONE bullet must be evidence-based and include [@guideline:doc_id | Page xx] or [@pubmed | PMID].\nIf you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].\nIf discussions mentioned specific evidence, you may reference it with appropriate tags.", "assistant_reply": "- Confirm final histology as pure high‑grade ovarian clear cell carcinoma; no morphologic evidence of mixed or alternative histotype. [@guideline:esgo_esmo_esp_consensus_ovariancancer_2024__v00000000 | Page 6]\n\n- Clearly state MMR proficiency (MLH1/MSH2/MSH6/PMS2 retained) and ER/PR focal expression in the pathology addendum. [@2022-03-28 | LAB]\n\n- Request integrated molecular addendum summarizing HRD‑negative, BRCA‑wild‑type status and detailing germline ATM p.Y316C classification/implications. [@OH2203828 | Genomics]", "timestamp": "2026-01-21T07:03:10.943536"}], "nuclear": [{"role": "nuclear", "user_message": "Give INITIAL opinion (use ONLY your system-provided patient facts).\nReturn up to 3 bullets, each ≤20 words.\nIf key data missing, say exactly what needs updating.\nAt least ONE bullet must be evidence-based and include [@guideline:doc_id | Page xx] or [@pubmed | PMID].\nIf you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].\nFor clinical reports, use actual report_id from report data with type: [@actual_report_id | LAB], [@actual_report_id | Genomics], [@actual_report_id | MR], [@actual_report_id | CT] (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy].", "assistant_reply": "- Known pelvic presacral mass with sacral and right iliac bone involvement; PET could better define osseous/metastatic extent and activity [@2022-12-29|MR | MR].\n\n- Progressive multifocal hepatic metastases on CT; PET would refine whole‑body metastatic burden and extrahepatic disease mapping [@2022-12-29|CT | CT].\n\n- For advanced/recurrent ovarian carcinoma, PET‑CT is an acceptable staging option complementing MRI/CT for planning [@guideline:esgo_esmo_esp_consensus_ovariancancer_2024__v00000000 | Page 8].", "timestamp": "2026-01-21T07:02:08.063968"}, {"role": "nuclear", "user_message": "ROLE: nuclear. VISIT: 2023-01-03 08:53:29.260000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\n[MDT_GLOBAL_KNOWLEDGE]\nKey Knowledge:\n- Platinum‑resistant recurrent high‑grade clear cell ovarian carcinoma with rapid systemic progression (liver, presacral/sacral, pelvic bone, peritoneal nodules).\n- Rising tumor markers (CA125/CA19‑9) consistent with radiologic progression.\n- Significant anemia (Hgb 74 g/L) requiring correction; renal/hepatic function otherwise acceptable for systemic therapy.\n- Histology/IHC confirm clear cell carcinoma; MMR proficient (no MSI‑H), BRCA1/2 and HRD negative; germline ATM variant of note without clear targetable HRR implication.\n- Current CT/MRI show extensive hepatic and pelvic osseous disease; PET‑CT could further refine whole‑body metastatic burden.\n\nControversies:\n- Optimal choice and intensity of non‑platinum systemic regimen in the context of severe anemia and clear cell histology.\n- Added value and timing of PET‑CT given already advanced disease documented on CT/MRI.\n- Relevance and actionability of germline ATM variant in this clinical context.\n\nMissing Info:\n- ECOG performance status and detailed symptom burden (pain, skeletal symptoms, functional impact).\n- Full toxicity history from prior therapies and current medications.\n- Most recent cross‑sectional imaging dates and formal reports; any interval changes since last CT/MRI.\n- Detailed NGS interpretive report regarding ATM variant classification and potential clinical trial options.\n- Current anemia work‑up (iron studies, B12/folate, hemolysis markers) and transfusion history.\n\nWorking Plan:\n- Optimize anemia before further systemic therapy (transfusion +/- iron/other as indicated) and reassess fitness for treatment.\n- Document ECOG status, pain/skeletal symptoms, and prior treatment toxicities to guide regimen selection.\n- Confirm and review latest CT/MRI; consider PET‑CT for full metastatic mapping if results would alter systemic or palliative local approaches.\n- Discuss non‑platinum systemic options appropriate for platinum‑resistant clear cell histology, tailored to organ function and performance status.\n- Review full NGS report including ATM variant in molecular tumor board context for potential trial eligibility or targeted strategies.\n\nAllowed targets: [chair,oncologist,radiologist,pathologist]\n\nEVIDENCE TAGS (if your message references evidence):\n- Any factual statement about past tests/treatments must include [@actual_report_id | LAB/Genomics/MR/CT] using actual report_id from report data (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy]. or say unknown.\n- Any statement derived from guideline or PubMed literature must include [@guideline:doc_id | Page xx] or [@pubmed | PMID].\n- If you cite guideline/PubMed evidence or reference clinical trials, include appropriate tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].\n\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences with evidence tags if applicable>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"yes\",\"messages\":[{\"target\":\"radiologist\",\"message\":\"From nuclear perspective, no actual PET report is available; if PET-CT is intended to guide further local measures, please confirm whether any PET has been performed after 2022-12-29 cross-sectional imaging or explicitly schedule one, as current staging relies solely on MRI/CT [@2022-12-29|MR | MR][@2022-12-29|CT | CT].\",\"why\":\"missing\"}]}", "timestamp": "2026-01-21T07:02:39.487001"}, {"role": "nuclear", "user_message": "Given MDT context:\n[MDT_GLOBAL_KNOWLEDGE]\nKey Knowledge:\n- Platinum‑resistant recurrent high‑grade clear cell ovarian carcinoma with rapid systemic progression (liver, presacral/sacral, pelvic bone, peritoneal nodules).\n- Rising tumor markers (CA125/CA19‑9) consistent with radiologic progression.\n- Significant anemia (Hgb 74 g/L) requiring correction; renal/hepatic function otherwise acceptable for systemic therapy.\n- Histology/IHC confirm clear cell carcinoma; MMR proficient (no MSI‑H), BRCA1/2 and HRD negative; germline ATM variant of note without clear targetable HRR implication.\n- Current CT/MRI show extensive hepatic and pelvic osseous disease; PET‑CT could further refine whole‑body metastatic burden.\n\nControversies:\n- Optimal choice and intensity of non‑platinum systemic regimen in the context of severe anemia and clear cell histology.\n- Added value and timing of PET‑CT given already advanced disease documented on CT/MRI.\n- Relevance and actionability of germline ATM variant in this clinical context.\n\nMissing Info:\n- ECOG performance status and detailed symptom burden (pain, skeletal symptoms, functional impact).\n- Full toxicity history from prior therapies and current medications.\n- Most recent cross‑sectional imaging dates and formal reports; any interval changes since last CT/MRI.\n- Detailed NGS interpretive report regarding ATM variant classification and potential clinical trial options.\n- Current anemia work‑up (iron studies, B12/folate, hemolysis markers) and transfusion history.\n\nWorking Plan:\n- Optimize anemia before further systemic therapy (transfusion +/- iron/other as indicated) and reassess fitness for treatment.\n- Document ECOG status, pain/skeletal symptoms, and prior treatment toxicities to guide regimen selection.\n- Confirm and review latest CT/MRI; consider PET‑CT for full metastatic mapping if results would alter systemic or palliative local approaches.\n- Discuss non‑platinum systemic options appropriate for platinum‑resistant clear cell histology, tailored to organ function and performance status.\n- Review full NGS report including ATM variant in molecular tumor board context for potential trial eligibility or targeted strategies.\n\n[RECENT_DELTAS]\n[R1T1 DELTA] 2 | LAB] | radiologist->chair(missing): Imaging facts in the MDT summary (widespread hepatic and pelvic osseous disease) match only the 2022-12-29 CT/MR; please confirm there is no more recent CT/MRI, otherwise updated scans are needed to guide current decisions [@2022-12-29|MR | MR] [@2022-12-29|CT | CT]. | pathologist->oncologist(missing): From pathology side, key missing item is a detailed NGS interpretive report classifying the germline ATM p.Y316C variant (pathogenic vs VUS) and commenting on trial eligibility. [@OH2203828 | Genomics] | nuclear->radiologist(missing): From nuclear perspective, no actual PET report is available; if PET-CT is intended to guide further local measures, please confirm whether any PET has been performed after 2022-12-29 cross-sectional imaging or explicitly schedule one, as current staging relies solely on MRI/CT [@2022-12-29|MR | MR][@2022-12-29|CT | CT].\n\nDISCUSSION HISTORY (this round):\nTurn 1: chair→oncologist: Before finalizing a non‑platinum regimen, we must correct severe anemia and document ECOG and prior toxicities; otherwise regimen intensity decisions risk excess toxicity [@20230103|5600862 | LAB]. | chair→radiologist: Please confirm whether any CT/MRI after 2022‑12‑29/30 exist and, if not, whether PET‑CT would realistically change local vs systemic planning [@2022-12-29|MR] [@2022-12-29|CT]. | chair→pathologist: Kindly clarify in the report whether any features suggest alternative histotype or mixed tumor, as this could alter systemic strategy [@2022-03-28 | CT].\n\nProvide FINAL refined plan based on the above context and discussions.\nUp to 3 bullets, each ≤20 words.\nAny factual claim must include [@actual_report_id | LAB/Genomics/MR/CT] using actual report_id from report data (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy]. or say unknown.\nAt least ONE bullet must be evidence-based and include [@guideline:doc_id | Page xx] or [@pubmed | PMID].\nIf you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].\nIf discussions mentioned specific evidence, you may reference it with appropriate tags.", "assistant_reply": "- No PET-CT yet; recommend whole‑body FDG PET-CT only if updated mapping would alter local palliation or systemic strategy [@2022-12-29|MR | MR][@2022-12-29|CT | CT][@guideline:esgo_esmo_esp_consensus_ovariancancer_2024__v00000000 | Page 8].\n\n- Current staging rests on 2022-12-29 CT/MR showing progressive liver and presacral/sacral disease; repeat cross‑sectional imaging before PET if outdated [@2022-12-29|MR | MR][@2022-12-29|CT | CT].\n\n- When performed, PET interpretation should focus on defining true osseous and extrahepatic metastatic burden beyond MRI/CT, to refine radiotherapy targeting [@2022-12-29|MR | MR][@2022-12-29|CT | CT].", "timestamp": "2026-01-21T07:03:25.435321"}], "assistant": [{"role": "assistant", "user_message": "Summarize expert opinions concisely for MDT.\n{\"chair\":\"- Platinum‑resistant metastatic clear cell ovarian carcinoma with rapid progression in liver, presacral/sacral and bone; systemic non‑platinum regimen indicated [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 10].  \\n\\n- Baseline anemia (Hgb 74 g/L) requires correction and transfusion/iron assessment before starting further systemic therapy [@20230103|5600862 | LAB].  \\n\\n- Before firm plan: document ECOG status, pain/skeletal symptoms, prior toxicities, and confirm current MRI/CT images and full NGS interpretation details [@OH2203828 | Genomics].\",\"oncologist\":\"- Platinum-resistant recurrent clear cell ovarian carcinoma with rising CA125/CA19-9 and new liver/bone metastases; systemic relapse-therapy category indicated. [@20221229|9703212 | LAB] [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 10]  \\n\\n- Significant anemia (Hgb 74 g/L) may limit intensity of cytotoxic systemic therapy; requires optimization/transfusion before full-dose treatment. [@20230103|5600862 | LAB]  \\n\\n- Organ function (renal/hepatic) appears acceptable for most systemic options; confirm current performance status and recent cross-sectional imaging details for planning. [@20221229|8300002 | LAB]\",\"radiologist\":\"- Progressive presacral pelvic mass with sacral and right iliac bone involvement; multiple stable pelvic mesenteric/peritoneal nodules suspicious for metastases [@2022-10-24|MR | MR] [@2022-12-29|MR | MR].  \\n\\n- Liver: multiple metastatic nodules increasing in number and size; spleen with patchy low‑density area possibly infarct, needs clinical correlation [@2022-12-29|CT | CT].  \\n\\n- Cross‑sectional CT/MRI adequately demonstrate advanced, recurrent disease distribution for MDT treatment planning [@guideline:esgo_esmo_esp_consensus_ovariancancer_2024__v00000000 | Page 8].\",\"pathologist\":\"- Morphology and IHC strongly support recurrent ovarian clear cell carcinoma involving rectosigmoid, retroperitoneum, and vagina, high‑grade. [@guideline:esgo_esmo_esp_consensus_ovariancancer_2024__v00000000 | Page 6]\\n\\n- MMR proteins intact; no evidence of MMR deficiency/MSI‑H on IHC. [@2022-03-28 | LAB]\\n\\n- Comprehensive NGS: germline ATM p.Y316C; BRCA1/2 and HRD negative; no other pathogenic HRR variants detected. [@OH2203828 | Genomics]\",\"nuclear\":\"- Known pelvic presacral mass with sacral and right iliac bone involvement; PET could better define osseous/metastatic extent and activity [@2022-12-29|MR | MR].\\n\\n- Progressive multifocal hepatic metastases on CT; PET would refine whole‑body metastatic burden and extrahepatic disease mapping [@2022-12-29|CT | CT].\\n\\n- For advanced/recurrent ovarian carcinoma, PET‑CT is an acceptable staging option complementing MRI/CT for planning [@guideline:esgo_esmo_esp_consensus_ovariancancer_2024__v00000000 | Page 8].\"}\n\nOutput:\nKey Knowledge:\n- ...\nControversies:\n- ...\nMissing Info:\n- ...\nWorking Plan:\n- ...", "assistant_reply": "Key Knowledge:\n- Platinum‑resistant recurrent high‑grade clear cell ovarian carcinoma with rapid systemic progression (liver, presacral/sacral, pelvic bone, peritoneal nodules).\n- Rising tumor markers (CA125/CA19‑9) consistent with radiologic progression.\n- Significant anemia (Hgb 74 g/L) requiring correction; renal/hepatic function otherwise acceptable for systemic therapy.\n- Histology/IHC confirm clear cell carcinoma; MMR proficient (no MSI‑H), BRCA1/2 and HRD negative; germline ATM variant of note without clear targetable HRR implication.\n- Current CT/MRI show extensive hepatic and pelvic osseous disease; PET‑CT could further refine whole‑body metastatic burden.\n\nControversies:\n- Optimal choice and intensity of non‑platinum systemic regimen in the context of severe anemia and clear cell histology.\n- Added value and timing of PET‑CT given already advanced disease documented on CT/MRI.\n- Relevance and actionability of germline ATM variant in this clinical context.\n\nMissing Info:\n- ECOG performance status and detailed symptom burden (pain, skeletal symptoms, functional impact).\n- Full toxicity history from prior therapies and current medications.\n- Most recent cross‑sectional imaging dates and formal reports; any interval changes since last CT/MRI.\n- Detailed NGS interpretive report regarding ATM variant classification and potential clinical trial options.\n- Current anemia work‑up (iron studies, B12/folate, hemolysis markers) and transfusion history.\n\nWorking Plan:\n- Optimize anemia before further systemic therapy (transfusion +/- iron/other as indicated) and reassess fitness for treatment.\n- Document ECOG status, pain/skeletal symptoms, and prior treatment toxicities to guide regimen selection.\n- Confirm and review latest CT/MRI; consider PET‑CT for full metastatic mapping if results would alter systemic or palliative local approaches.\n- Discuss non‑platinum systemic options appropriate for platinum‑resistant clear cell histology, tailored to organ function and performance status.\n- Review full NGS report including ATM variant in molecular tumor board context for potential trial eligibility or targeted strategies.", "timestamp": "2026-01-21T07:02:20.233693"}, {"role": "assistant", "user_message": "You are MDT assistant. Update MDT GLOBAL structured memory by integrating ROUND FINAL plans. Keep the same output format with: Key Knowledge / Controversies / Missing Info / Working Plan.\n\nCURRENT_MDT_GLOBAL_KNOWLEDGE:\n[MDT_GLOBAL_KNOWLEDGE]\nKey Knowledge:\n- Platinum‑resistant recurrent high‑grade clear cell ovarian carcinoma with rapid systemic progression (liver, presacral/sacral, pelvic bone, peritoneal nodules).\n- Rising tumor markers (CA125/CA19‑9) consistent with radiologic progression.\n- Significant anemia (Hgb 74 g/L) requiring correction; renal/hepatic function otherwise acceptable for systemic therapy.\n- Histology/IHC confirm clear cell carcinoma; MMR proficient (no MSI‑H), BRCA1/2 and HRD negative; germline ATM variant of note without clear targetable HRR implication.\n- Current CT/MRI show extensive hepatic and pelvic osseous disease; PET‑CT could further refine whole‑body metastatic burden.\n\nControversies:\n- Optimal choice and intensity of non‑platinum systemic regimen in the context of severe anemia and clear cell histology.\n- Added value and timing of PET‑CT given already advanced disease documented on CT/MRI.\n- Relevance and actionability of germline ATM variant in this clinical context.\n\nMissing Info:\n- ECOG performance status and detailed symptom burden (pain, skeletal symptoms, functional impact).\n- Full toxicity history from prior therapies and current medications.\n- Most recent cross‑sectional imaging dates and formal reports; any interval changes since last CT/MRI.\n- Detailed NGS interpretive report regarding ATM variant classification and potential clinical trial options.\n- Current anemia work‑up (iron studies, B12/folate, hemolysis markers) and transfusion history.\n\nWorking Plan:\n- Optimize anemia before further systemic therapy (transfusion +/- iron/other as indicated) and reassess fitness for treatment.\n- Document ECOG status, pain/skeletal symptoms, and prior treatment toxicities to guide regimen selection.\n- Confirm and review latest CT/MRI; consider PET‑CT for full metastatic mapping if results would alter systemic or palliative local approaches.\n- Discuss non‑platinum systemic options appropriate for platinum‑resistant clear cell histology, tailored to organ function and performance status.\n- Review full NGS report including ATM variant in molecular tumor board context for potential trial eligibility or targeted strategies.\n\nROUND_1_FINAL_PLANS_JSON:\n{\"chair\":\"- Correct severe anemia and clarify ECOG, symptom burden, prior toxicities before initiating any non‑platinum systemic therapy [@20230103|5600862 | LAB].  \\n\\n- Proceed with non‑platinum systemic regimen suitable for platinum‑resistant clear cell disease once optimized, considering trial options and ATM‑related eligibility [@OH2203828 | Genomics][@pubmed | 30109783].  \\n\\n- Update staging with latest CT/MRI; add PET‑CT only if results would change systemic versus palliative local strategy [@2022-12-29|MR | MR][@2022-12-29|CT | CT][@guideline:esgo_esmo_esp_consensus_ovariancancer_2024__v00000000 | Page 8].\",\"oncologist\":\"- Correct anemia and document ECOG, symptom burden, and prior toxicities before initiating individualized non‑platinum relapse systemic therapy. [@20230103|5600862 | LAB] [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 10]  \\n\\n- Proceed with systemic relapse‑therapy planning assuming clear cell histology, MMR proficiency, BRCA/HRD negativity, and germline ATM variant per NGS. [@OH2203828 | Genomics] [@pubmed | 30109783]  \\n\\n- Confirm no post‑2022‑12‑29 CT/MRI; order PET‑CT only if results would modify systemic choice or local palliative interventions. [@2022-12-29|MR | MR] [@2022-12-29|CT | CT]\",\"radiologist\":\"- No cross‑sectional imaging is available after 2022‑12‑29; current staging relies on that CT/MR set [@2022-12-29|MR | MR] [@2022-12-29|CT | CT].  \\n\\n- Before PET‑CT, clarify whether updated CT/MR is planned; PET should be reserved for scenarios where it may alter management [@guideline:esgo_esmo_esp_consensus_ovariancancer_2024__v00000000 | Page 8].  \\n\\n- Document any new focal bone or neurologic symptoms to prioritize targeted imaging (e.g., spine/pelvis MRI) if clinically indicated [@2022-12-29|MR | MR].\",\"pathologist\":\"- Confirm final histology as pure high‑grade ovarian clear cell carcinoma; no morphologic evidence of mixed or alternative histotype. [@guideline:esgo_esmo_esp_consensus_ovariancancer_2024__v00000000 | Page 6]\\n\\n- Clearly state MMR proficiency (MLH1/MSH2/MSH6/PMS2 retained) and ER/PR focal expression in the pathology addendum. [@2022-03-28 | LAB]\\n\\n- Request integrated molecular addendum summarizing HRD‑negative, BRCA‑wild‑type status and detailing germline ATM p.Y316C classification/implications. [@OH2203828 | Genomics]\",\"nuclear\":\"- No PET-CT yet; recommend whole‑body FDG PET-CT only if updated mapping would alter local palliation or systemic strategy [@2022-12-29|MR | MR][@2022-12-29|CT | CT][@guideline:esgo_esmo_esp_consensus_ovariancancer_2024__v00000000 | Page 8].\\n\\n- Current staging rests on 2022-12-29 CT/MR showing progressive liver and presacral/sacral disease; repeat cross‑sectional imaging before PET if outdated [@2022-12-29|MR | MR][@2022-12-29|CT | CT].\\n\\n- When performed, PET interpretation should focus on defining true osseous and extrahepatic metastatic burden beyond MRI/CT, to refine radiotherapy targeting [@2022-12-29|MR | MR][@2022-12-29|CT | CT].\"}", "assistant_reply": "Key Knowledge:\n- Platinum‑resistant recurrent high‑grade clear cell ovarian carcinoma with rapid systemic progression (liver, presacral/sacral, pelvic bone, peritoneal nodules).\n- Rising CA125/CA19‑9 consistent with radiologic progression.\n- Significant anemia (Hgb 74 g/L) requiring correction; renal/hepatic function acceptable for systemic therapy once optimized.\n- Histology/IHC confirm pure high‑grade ovarian clear cell carcinoma; MMR proficient (MLH1/MSH2/MSH6/PMS2 retained), ER/PR focally expressed; BRCA1/2 and HRD negative; germline ATM p.Y316C variant noted.\n- Current staging is based on 2022‑12‑29 CT/MR showing progressive liver and presacral/sacral disease; PET‑CT not yet performed and considered only if management‑altering.\n\nControversies:\n- Optimal non‑platinum relapse regimen and intensity for platinum‑resistant clear cell histology in the setting of severe baseline anemia.\n- Threshold for ordering PET‑CT versus repeating CT/MR alone, and whether PET findings would realistically change systemic versus palliative local strategies.\n- Clinical actionability and trial relevance of the germline ATM variant in this patient’s context.\n\nMissing Info:\n- ECOG performance status and detailed symptom burden (pain, skeletal, neurologic, functional impact).\n- Full prior treatment toxicity history and current medications.\n- Confirmation that no post‑2022‑12‑29 CT/MRI exists; need for updated cross‑sectional imaging if disease status is uncertain.\n- Integrated NGS/molecular addendum summarizing HRD‑negative, BRCA‑wild‑type status and detailed classification/implications of ATM p.Y316C.\n- Current anemia work‑up (iron/B12/folate, hemolysis markers) and transfusion/iron replacement history.\n\nWorking Plan:\n- Correct severe anemia and complete anemia work‑up; then reassess suitability for full‑dose non‑platinum systemic therapy.\n- Document ECOG, symptom burden (including bone/neurologic symptoms), and prior toxicities to individualize relapse systemic regimen and supportive care.\n- Confirm absence of more recent imaging; update staging with new CT/MR if prior (2022‑12‑29) set is outdated or discordant with current symptoms.\n- Consider FDG PET‑CT only if additional disease mapping would change systemic regimen choice, clinical trial eligibility, or local palliative interventions (e.g., radiotherapy targeting).\n- Finalize pathology/molecular documentation: issue addendum confirming pure clear cell histology, MMR proficiency, ER/PR status, and integrated summary of HRD‑negative, BRCA‑wild‑type, and ATM variant, to support systemic and trial planning.", "timestamp": "2026-01-21T07:03:30.107532"}], "trial_selector": [{"role": "trial_selector", "user_message": "You are an MDT assistant for gynecologic oncology clinical trial matching.\n\nCRITICAL BEHAVIOR:\n- You MUST NOT ask the user any questions.\n- You MUST NOT request additional information.\n- You MUST NOT output anything except the required template.\n- Use ONLY the provided PATIENT CASE text and AVAILABLE TRIALS list.\n- If eligibility is unclear due to missing key facts, you MUST output None.\n\nPATIENT CASE (facts only; do not infer):\n# ORIGINAL CASE JSON\n{\"CASE_CORE\":{\"ADJUVANT_TREATMENT\":{\"cycles_or_courses\":\"6\",\"given\":\"Yes\",\"regimens\":[\"白紫+卡铂\"]},\"BIOMARKERS\":{\"AFP\":\"<0.91 ng/ml (2022-10-12)\",\"CA125\":\"933.00 U/ml (2022-12-29)\",\"HER2\":\"Unknown\",\"MSI\":\"Unknown\",\"PDL1_CPS\":\"Unknown\",\"TMB\":\"Unknown\"},\"BRCA1\":\"Unknown\",\"BRCA2\":\"Unknown\",\"CURRENT_STATUS\":\"Recurrent ovarian clear cell carcinoma with metastatic disease (liver, presacral/sacrum, right iliac bone) documented on imaging\",\"DIAGNOSIS\":{\"components\":[\"High-grade adenocarcinoma involving full-thickness intestinal wall\",\"Lymph node metastasis (4/15)\",\"Peritoneal/rectal/vaginal involvement described\"],\"histology\":\"透明细胞癌; 肠壁全层见高级别腺癌\",\"laterality\":\"Unknown\",\"primary\":\"卵巢癌复发\",\"site\":\"Ovary\"},\"HRD\":\"Unknown\",\"INITIAL_TREATMENT\":\"Unknown\",\"LINE_OF_THERAPY\":[{\"cycles\":\"6\",\"end_date\":\"2022-08-17\",\"intent\":\"Unknown\",\"line\":\"1L\",\"regimen\":\"白紫+卡铂\",\"start_date\":\"Unknown\"}],\"MAINTENANCE\":\"Unknown\",\"MAINTENANCE_DETAIL\":{\"end_date\":\"Unknown\",\"given\":\"Unknown\",\"regimens\":[],\"start_date\":\"Unknown\"},\"NEOADJUVANT\":\"Unknown\",\"PFI_days\":\"56\",\"PLATINUM_HISTORY\":[{\"PFI_days\":\"56\",\"end_date\":\"2022-08-17\",\"evidence\":\"Rise in CA125/CA19-9 on 2022-10-12\",\"evidence_type\":\"Biochemical\",\"first_relapse_date\":\"2022-10-12\",\"line\":\"1L\",\"start_date\":\"Unknown\",\"status\":\"Resistant\"}],\"PLATINUM_PFI_CURRENT\":\"56\",\"PLATINUM_STATUS\":\"Resistant\",\"PLATINUM_STATUS_CURRENT\":\"Resistant\",\"RELAPSE\":\"Yes\",\"RELAPSE_DATE\":{\"date\":\"2022-10-12\",\"evidence\":\"Elevated CA125 and CA19-9 on 2022-10-12; imaging (MRI 2022-10-24, CT 2022-10-25) supports recurrence\",\"type\":\"Biochemical\"},\"SCENE\":\"Platinum_resistant_relapse\",\"STAGE\":{\"stage_basis\":\"Unknown\",\"stage_system\":\"Unknown\",\"stage_text\":\"Unknown\"},\"SURGERY_DONE\":{\"date\":\"2022-03-28\",\"performed\":\"Yes\",\"procedure\":\"Tumor debulking + partial rectosigmoid resection + partial vaginectomy + retroperitoneal lesion resection + complex adhesiolysis + left ureteral stent placement + bladder repair\"},\"TIMELINE\":{\"constraints\":{\"max_events\":30,\"min_events\":3,\"must_include\":[\"first diagnostic imaging or pathology confirmation (if available)\"],\"ordering_rules\":{\"prioritize_last_event\":true}},\"events\":[{\"date\":\"2022-03-28\",\"description\":\"Cytoreductive surgery including partial rectosigmoid resection, partial vaginectomy, retroperitoneal lesion resection, left ureteral stent, bladder repair\",\"event_type\":\"Surgery\",\"key_result\":\"Tumor ~7x4x2.5 cm; full-thickness intestinal wall high-grade adenocarcinoma; consider ovarian clear cell carcinoma; 4/15 nodes positive\",\"regimen_or_test\":\"Surgical resection\"},{\"date\":\"2022-08-17\",\"description\":\"Completed 6 cycles of 白紫+卡铂 chemotherapy, last given 2022-08-17\",\"event_type\":\"Chemo\",\"key_result\":\"Post-chemo tumor markers reduced on 2022-08-15\",\"regimen_or_test\":\"白紫+卡铂\"},{\"date\":\"2022-10-12\",\"description\":\"Rising tumor markers indicating recurrence\",\"event_type\":\"Lab\",\"key_result\":\"CA19-9 77.20 U/ml; CA125 89.60 U/ml\",\"regimen_or_test\":\"Tumor markers\"},{\"date\":\"2022-10-24\",\"description\":\"Pelvic MRI shows presacral mass and pelvic mesenteric nodules; consider recurrence with sacral involvement\",\"event_type\":\"Imaging\",\"key_result\":\"Presacral lesion and pelvic mesenteric nodules, possible metastases\",\"regimen_or_test\":\"MRI pelvis\"},{\"date\":\"2022-10-25\",\"description\":\"CT shows multiple liver nodules, some new compared to prior\",\"event_type\":\"Imaging\",\"key_result\":\"Multiple hepatic metastatic nodules\",\"regimen_or_test\":\"CT abdomen\"},{\"date\":\"2022-12-29\",\"description\":\"Markedly elevated tumor markers consistent with progression\",\"event_type\":\"Lab\",\"key_result\":\"CA125 933.00 U/ml; CA19-9 229.00 U/ml; HE4 111.00 pmol/L\",\"regimen_or_test\":\"Tumor markers\"},{\"date\":\"2022-12-30\",\"description\":\"MRI/CT show increased presacral lesion, new right iliac bone nodule, increased hepatic metastases\",\"event_type\":\"Imaging\",\"key_result\":\"Progression of pelvic and hepatic metastatic disease\",\"regimen_or_test\":\"MRI pelvis; CT abdomen\"}]},\"VISIT_DATE\":\"2023-01-03\",\"first_relapse_date\":\"2022-10-12\",\"last_platinum_end_date\":\"2022-08-17\"},\"LAB_TRENDS\":{\"labs\":[{\"analyte\":\"CA125\",\"history\":[{\"date\":\"2022-08-15\",\"flag\":\"Unknown\",\"value\":\"14.90\"},{\"date\":\"2022-10-12\",\"flag\":\"↑\",\"value\":\"89.60\"},{\"date\":\"2022-11-17\",\"flag\":\"↑\",\"value\":\"403\"},{\"date\":\"2022-12-29\",\"flag\":\"↑\",\"value\":\"933.00\"}],\"latest\":{\"date\":\"2022-12-29\",\"flag\":\"↑\",\"value\":\"933.00\"},\"reference_range\":\"Unknown\",\"unit\":\"U/ml\"},{\"analyte\":\"CA19-9\",\"history\":[{\"date\":\"2022-08-15\",\"flag\":\"Unknown\",\"value\":\"7.16\"},{\"date\":\"2022-10-12\",\"flag\":\"↑\",\"value\":\"77.20\"},{\"date\":\"2022-12-29\",\"flag\":\"↑\",\"value\":\"229.00\"}],\"latest\":{\"date\":\"2022-12-29\",\"flag\":\"↑\",\"value\":\"229.00\"},\"reference_range\":\"Unknown\",\"unit\":\"U/ml\"},{\"analyte\":\"HE4\",\"history\":[{\"date\":\"2022-08-15\",\"flag\":\"↑\",\"value\":\"87.90\"},{\"date\":\"2022-10-12\",\"flag\":\"Unknown\",\"value\":\"59.70\"},{\"date\":\"2022-12-29\",\"flag\":\"↑\",\"value\":\"111.00\"}],\"latest\":{\"date\":\"2022-12-29\",\"flag\":\"↑\",\"value\":\"111.00\"},\"reference_range\":\"Unknown\",\"unit\":\"pmol/L\"},{\"analyte\":\"AFP\",\"history\":[{\"date\":\"2022-10-12\",\"flag\":\"Unknown\",\"value\":\"<0.91\"}],\"latest\":{\"date\":\"2022-10-12\",\"flag\":\"Unknown\",\"value\":\"<0.91\"},\"reference_range\":\"Unknown\",\"unit\":\"ng/ml\"}],\"milestones\":[{\"date\":\"2022-03-28\",\"description\":\"Primary cytoreductive surgery performed\",\"type\":\"Surgery\"},{\"date\":\"2022-08-17\",\"description\":\"Completed 6 cycles of 白紫+卡铂\",\"type\":\"ChemoEnd\"},{\"date\":\"2022-10-12\",\"description\":\"Biochemical relapse with rising tumor markers\",\"type\":\"Relapse\"}]},\"MED_ONC\":{\"current_regimen\":{\"cycle_info\":\"6 cycles of 白紫+卡铂, last 2022-08-17\",\"last_admin_date\":\"2022-08-17\",\"name\":\"Unknown\"},\"genetic_testing\":{\"germline\":[],\"somatic\":[]},\"monitoring_points\":[],\"planned_next_regimen\":\"Unknown\",\"prior_systemic_therapies\":[\"白紫+卡铂\"]},\"NUC_MED\":{\"studies\":[]},\"PATHOLOGY\":{\"specimens\":[{\"components\":[\"Tumor size ~7x4x2.5 cm\",\"Bilateral margins negative\",\"Pericolic lymph nodes 4/15 positive\",\"One tumor nodule (posterior bladder)\"],\"date\":\"2022-03-28\",\"diagnosis\":\"Consider ovarian clear cell carcinoma involvement; full-thickness intestinal wall high-grade adenocarcinoma\",\"grade\":\"High-grade\",\"ihc\":[{\"marker\":\"MLH1\",\"result\":\"+\"},{\"marker\":\"MSH6\",\"result\":\"+\"},{\"marker\":\"MSH2\",\"result\":\"+\"},{\"marker\":\"PMS2\",\"result\":\"+\"},{\"marker\":\"ER\",\"result\":\"partial+\"},{\"marker\":\"PR\",\"result\":\"few weak+\"},{\"marker\":\"P53\",\"result\":\"+/-\"},{\"marker\":\"WT1\",\"result\":\"-\"},{\"marker\":\"Ki-67\",\"result\":\"60%+\"},{\"marker\":\"HNF1B\",\"result\":\"+\"},{\"marker\":\"NapsinA\",\"result\":\"focal+\"},{\"marker\":\"P16\",\"result\":\"+\"},{\"marker\":\"PAX8\",\"result\":\"+\"},{\"marker\":\"SALL4\",\"result\":\"-\"},{\"marker\":\"ZBTB16\",\"result\":\"-\"}],\"involvement_sites\":[\"Rectosigmoid colon\",\"Left retroperitoneum\",\"Vagina\",\"Pericolic lymph nodes\",\"Posterior bladder nodule\"],\"laterality\":\"Unknown\",\"molecular\":[],\"raw_text\":\"卵巢恶性肿瘤：卵巢癌复发：术前CA125 45.7 CA199 161 HE4 562 2022.03.28在全麻下行“瘤体减灭术+直肠乙状结肠部分切除术+阴道部分切除术+腹膜后病损切除术+复杂肠粘连松解术+左输尿管支架置管术+膀胱修补术。（部分直乙结肠+左侧腹膜后肿瘤+部分阴道）肠壁全层见高级别腺癌，结合T2022-04771首先考虑为透明细胞癌，正在加做免疫组化进一步明确。肿块大小约7*4*2.5cm。双侧切缘阴性，肠周淋巴结（4/15）见癌转移，伴癌结节1枚。（膀胱后壁肿瘤）纤维脂肪组织，局灶纤维组织增生、含铁血黄素沉积、泡沫样组织反应，未见癌累及。补充诊断1：【补充报告】（部分直乙结肠+左侧腹膜后肿瘤+部分阴道）可符合卵巢透明细胞癌累及。免疫组化（HI22-06789）瘤细胞：MLH1(ES05)（+），MSH6（+），MSH2（+），PMS2（+），ER（部分+），PR（少弱+），P53（+/-），WT1（-），Ki-67（60%+），HNF1B（+），NapsinA（灶+），P16（+），PAX8（+），SALL4（-），ZBTB16（-）\",\"sample_type\":\"Surgical resection\",\"site\":\"Partial rectosigmoid + left retroperitoneal tumor + partial vagina\",\"tumor_size\":\"7 x 4 x 2.5 cm\",\"uncertainty_or_missing\":[\"BRCA/HRD testing not reported\"]}]},\"RADIOLOGY\":{\"next_imaging_plan\":{\"modality\":\"Unknown\",\"timing\":\"Unknown\"},\"studies\":[{\"anatomic_sites\":[\"Pelvis\"],\"date\":\"2022-10-24\",\"findings\":[\"Postoperative pelvis with presacral mass; pelvic mesenteric multiple enhancing small nodules\"],\"impression\":\"Consider recurrence with adjacent sacral involvement; pelvic mesenteric nodules likely metastases\",\"modality\":\"MRI\",\"trend_vs_prior\":\"Unknown\"},{\"anatomic_sites\":[\"Liver\"],\"date\":\"2022-10-25\",\"findings\":[\"Multiple intrahepatic nodules, some new compared to prior\"],\"impression\":\"Probable metastases in liver\",\"modality\":\"CT\",\"trend_vs_prior\":\"Worse\"},{\"anatomic_sites\":[\"Pelvis; sacrum; right iliac bone\"],\"date\":\"2022-12-30\",\"findings\":[\"Presacral lesion increased in size and heterogeneous enhancement; right iliac bone new enhancing nodule; pelvic mesenteric nodules similar\"],\"impression\":\"Progression of presacral disease with possible sacral and iliac bone involvement; peritoneal metastases possible\",\"modality\":\"MRI\",\"trend_vs_prior\":\"Worse\"},{\"anatomic_sites\":[\"Liver; spleen\"],\"date\":\"2022-12-30\",\"findings\":[\"Multiple hepatic metastatic nodules increased in number and size; splenic patchy shadow suggesting possible infarct\"],\"impression\":\"Progression of hepatic metastases\",\"modality\":\"CT\",\"trend_vs_prior\":\"Worse\"}]},\"TIMELINE\":{\"constraints\":{\"max_events\":30,\"min_events\":3,\"must_include\":[\"first diagnostic imaging or pathology confirmation (if available)\"],\"ordering_rules\":{\"prioritize_last_event\":true}},\"events\":[{\"date\":\"2022-03-28\",\"description\":\"Cytoreductive surgery including partial rectosigmoid resection, partial vaginectomy, retroperitoneal lesion resection, left ureteral stent, bladder repair\",\"event_type\":\"Surgery\",\"key_result\":\"Tumor ~7x4x2.5 cm; full-thickness intestinal wall high-grade adenocarcinoma; consider ovarian clear cell carcinoma; 4/15 nodes positive\",\"regimen_or_test\":\"Surgical resection\"},{\"date\":\"2022-08-17\",\"description\":\"Completed 6 cycles of 白紫+卡铂 chemotherapy, last given 2022-08-17\",\"event_type\":\"Chemo\",\"key_result\":\"Post-chemo tumor markers reduced on 2022-08-15\",\"regimen_or_test\":\"白紫+卡铂\"},{\"date\":\"2022-10-12\",\"description\":\"Rising tumor markers indicating recurrence\",\"event_type\":\"Lab\",\"key_result\":\"CA19-9 77.20 U/ml; CA125 89.60 U/ml\",\"regimen_or_test\":\"Tumor markers\"},{\"date\":\"2022-10-24\",\"description\":\"Pelvic MRI shows presacral mass and pelvic mesenteric nodules; consider recurrence with sacral involvement\",\"event_type\":\"Imaging\",\"key_result\":\"Presacral lesion and pelvic mesenteric nodules, possible metastases\",\"regimen_or_test\":\"MRI pelvis\"},{\"date\":\"2022-10-25\",\"description\":\"CT shows multiple liver nodules, some new compared to prior\",\"event_type\":\"Imaging\",\"key_result\":\"Multiple hepatic metastatic nodules\",\"regimen_or_test\":\"CT abdomen\"},{\"date\":\"2022-12-29\",\"description\":\"Markedly elevated tumor markers consistent with progression\",\"event_type\":\"Lab\",\"key_result\":\"CA125 933.00 U/ml; CA19-9 229.00 U/ml; HE4 111.00 pmol/L\",\"regimen_or_test\":\"Tumor markers\"},{\"date\":\"2022-12-30\",\"description\":\"MRI/CT show increased presacral lesion, new right iliac bone nodule, increased hepatic metastases\",\"event_type\":\"Imaging\",\"key_result\":\"Progression of pelvic and hepatic metastatic disease\",\"regimen_or_test\":\"MRI pelvis; CT abdomen\"}]}}\n\n# MUTATION / GENETIC REPORTS (Full Text for Trial Matching)\n⚠️ COMPREHENSIVE NGS PANEL (~20,000 genes) - INTERPRETATION RULES:\n• '未检出' (not detected) = NO pathogenic mutation found\n• '（视为阴性）' (considered negative) = NO pathogenic mutation found\n• '阴性' (negative) = negative result\n• Genes with specific variants (e.g., 'NM_xxx:exon:c.xxx:p.xxx') = POSITIVE mutation\n• If a gene is NOT mentioned, it means NO pathogenic mutation (comprehensive panel)\n\n## Mutation Report 1 (ID: OH2203828, Date: 2022-04-18)\nATM NM_000051:exon8:c.A947G:p.Y316C（胚系）；HRD 阴性；BRCA1 胚系和体系未检出致病突变（视为阴性）；BRCA2 胚系和体系未检出致病突变（视为阴性）；TP53 胚系和体系未检出致病突变（视为阴性）；ARID1A 胚系和体系未检出致病突变（视为阴性）；PTEN 胚系和体系未检出致病突变（视为阴性）；PIK3CA 胚系和体系未检出致病突变（视为阴性）；PALB2 胚系和体系未检出致病突变（视为阴性）；RAD51D 胚系和体系未检出致病突变（视为阴性）；BRIP1 胚系和体系未检出致病突变（视为阴性）；BARD1 胚系和体系未检出致病突变（视为阴性）\n\n\nAVAILABLE TRIALS (compact; use id/name exactly as shown):\n[\n  {\n    \"id\": \"345\",\n    \"name\": \" 评估JSKN003在中国晚期恶性实体瘤受试者中的安全性、耐受性、药代动力学/药效学以及抗肿瘤活性的I/II期临床研究\",\n    \"phase\": \"II期\",\n    \"conditions\": null,\n    \"line_of_therapy\": \"2、3、4L\",\n    \"biomarker\": null,\n    \"doctor\": \"李佳佳\",\n    \"sponsor\": \"江苏康宁杰瑞生物制药有限公司\",\n    \"lead_or_participation\": \"牵头\",\n    \"treatment\": \"JSKN003-102（ADC，靶向HER2，毒性分子：拓扑异构酶I 抑制剂）\",\n    \"key_inclusion\": \"1、HER2 表达（IHC≥1+）\\n\\n2、经标准治疗失败、不能耐受标准治疗\\n\\n或缺乏有效治疗手段的受试者；\",\n    \"key_exclusion\": \"\",\n    \"contacts\": [\n      \"王 涛\"\n    ],\n    \"phones\": [\n      \"18721569326\"\n    ],\n    \"_raw\": {\n      \"id\": \"345\",\n      \"项目名称\": \" 评估JSKN003在中国晚期恶性实体瘤受试者中的安全性、耐受性、药代动力学/药效学以及抗肿瘤活性的I/II期临床研究\",\n      \"医生\": \"李佳佳\",\n      \"试验治疗/用药\": \"JSKN003-102（ADC，靶向HER2，毒性分子：拓扑异构酶I 抑制剂）\",\n      \"期别\": \"II期\",\n      \"申请单位\": \"江苏康宁杰瑞生物制药有限公司\",\n      \"牵头/参与\": \"牵头\",\n      \"目标受试者治疗线数\": \"2、3、4L\",\n      \"入组排除标准\": \"1、HER2 表达（IHC≥1+）<br />\\r\\n2、经标准治疗失败、不能耐受标准治疗<br />\\r\\n或缺乏有效治疗手段的受试者；<br />\",\n      \"联系人\": [\n        \"王 涛\"\n      ],\n      \"联系电话\": [\n        \"18721569326\"\n      ]\n    }\n  },\n  {\n    \"id\": \"346\",\n    \"name\": \"一项评价Trastuzumab Deruxtecan (T-DXd DS-8201a）治疗选定 HER2过表达肿瘤患者的有效性和安全性的多中心、开放性 II期研究（ DESTINY-PanTumor03)\",\n    \"phase\": \"II期\",\n    \"conditions\": null,\n    \"line_of_therapy\": \"＞1线\",\n    \"biomarker\": null,\n    \"doctor\": \"朱 俊\",\n    \"sponsor\": \"阿斯利康投资（中国）有限公司\",\n    \"lead_or_participation\": \"牵头\",\n    \"treatment\": \"Trastuzumab Deruxtecan（ADC，靶向HER2，毒性分子：拓扑异构酶I 抑制剂）\",\n    \"key_inclusion\": \"1、可预筛检测HER2 要求HER2 过表达（IHC≥1+）\\n\\n2、经标准治疗失败、不能耐受标准治疗\\n\\n或缺乏有效治疗手段的受试者；\",\n    \"key_exclusion\": \"\",\n    \"contacts\": [\n      \"江文燕\"\n    ],\n    \"phones\": [\n      \"15664735519\"\n    ],\n    \"_raw\": {\n      \"id\": \"346\",\n      \"项目名称\": \"一项评价Trastuzumab Deruxtecan (T-DXd DS-8201a）治疗选定 HER2过表达肿瘤患者的有效性和安全性的多中心、开放性 II期研究（ DESTINY-PanTumor03)\",\n      \"医生\": \"朱 俊\",\n      \"试验治疗/用药\": \"Trastuzumab Deruxtecan（ADC，靶向HER2，毒性分子：拓扑异构酶I 抑制剂）\",\n      \"期别\": \"II期\",\n      \"申请单位\": \"阿斯利康投资（中国）有限公司\",\n      \"牵头/参与\": \"牵头\",\n      \"目标受试者治疗线数\": \"＞1线\",\n      \"入组排除标准\": \"1、可预筛检测HER2 要求HER2 过表达（IHC≥1+）<br />\\r\\n2、经标准治疗失败、不能耐受标准治疗<br />\\r\\n或缺乏有效治疗手段的受试者；<br />\",\n      \"联系人\": [\n        \"江文燕\"\n      ],\n      \"联系电话\": [\n        \"15664735519\"\n      ]\n    }\n  },\n  {\n    \"id\": \"348\",\n    \"name\": \"一项评估MRG004A在组织因子阳性的晚期或转移性实体瘤患者中的安全性、耐受性、有效性和药代动力学的开放、多中心、I/II期剂量递增和扩展临床研究\",\n    \"phase\": \"I期\",\n    \"conditions\": null,\n    \"line_of_therapy\": \"2L、3L\",\n    \"biomarker\": null,\n    \"doctor\": \"郭勤浩、 Ⅰ期： 刘汝娇、 高水平、 陈 阳\",\n    \"sponsor\": \" 上海美雅珂生物技术有限责任公司\",\n    \"lead_or_participation\": \"牵头\",\n    \"treatment\": \"MRG004A（ADC，靶向组织因子（tissue factor，TF））\",\n    \"key_inclusion\": \"1、必须有组织学或细胞学证实的不切除或转移性肿瘤，标准治疗期间进展或经治后复发、进展。\",\n    \"key_exclusion\": \"\",\n    \"contacts\": [\n      \"杨 珂\"\n    ],\n    \"phones\": [\n      \"17774582517\"\n    ],\n    \"_raw\": {\n      \"id\": \"348\",\n      \"项目名称\": \"一项评估MRG004A在组织因子阳性的晚期或转移性实体瘤患者中的安全性、耐受性、有效性和药代动力学的开放、多中心、I/II期剂量递增和扩展临床研究\",\n      \"医生\": \"郭勤浩、 Ⅰ期： 刘汝娇、 高水平、 陈 阳\",\n      \"试验治疗/用药\": \"MRG004A（ADC，靶向组织因子（tissue factor，TF））\",\n      \"期别\": \"I期\",\n      \"申请单位\": \" 上海美雅珂生物技术有限责任公司\",\n      \"牵头/参与\": \"牵头\",\n      \"目标受试者治疗线数\": \"2L、3L\",\n      \"入组排除标准\": \"1、必须有组织学或细胞学证实的不切除或转移性肿瘤，标准治疗期间进展或经治后复发、进展。\",\n      \"联系人\": [\n        \"杨 珂\"\n      ],\n      \"联系电话\": [\n        \"17774582517\"\n      ]\n    }\n  },\n  {\n    \"id\": \"350\",\n    \"name\": \"评价注射用BL-B01D1在复发或转移性妇科恶性肿瘤等多种实体瘤患者中的安全性、耐受性、药代动力学及有效性的Ib/II期临床研究\",\n    \"phase\": \"Ⅰb/Ⅱ 期\",\n    \"conditions\": null,\n    \"line_of_therapy\": \"2L、3L\",\n    \"biomarker\": null,\n    \"doctor\": \"吴 勇、刘汝娇 、高水平\",\n    \"sponsor\": \"成都百利多特生物药业有限责任公司\",\n    \"lead_or_participation\": \"牵头\",\n    \"treatment\": \"单臂研究\\n\\n注射用BL-B01D1（ADC，靶向靶向 EGFR 和 HER3 靶点，毒性分子：拓扑异构酶I 抑制剂）\",\n    \"key_inclusion\": \"1、经病理组织学和/或细胞学确诊的标准治疗失败或不耐受或目前尚无标准治疗的复发或转移性妇科恶性肿瘤\",\n    \"key_exclusion\": \"\",\n    \"contacts\": [\n      \"李 想\"\n    ],\n    \"phones\": [\n      \"17703993082\"\n    ],\n    \"_raw\": {\n      \"id\": \"350\",\n      \"项目名称\": \"评价注射用BL-B01D1在复发或转移性妇科恶性肿瘤等多种实体瘤患者中的安全性、耐受性、药代动力学及有效性的Ib/II期临床研究\",\n      \"医生\": \"吴 勇、刘汝娇 、高水平\",\n      \"试验治疗/用药\": \"单臂研究<br />\\r\\n注射用BL-B01D1（ADC，靶向靶向 EGFR 和 HER3 靶点，毒性分子：拓扑异构酶I 抑制剂）<br />\",\n      \"期别\": \"Ⅰb/Ⅱ 期\",\n      \"申请单位\": \"成都百利多特生物药业有限责任公司\",\n      \"牵头/参与\": \"牵头\",\n      \"目标受试者治疗线数\": \"2L、3L\",\n      \"入组排除标准\": \"1、经病理组织学和/或细胞学确诊的标准治疗失败或不耐受或目前尚无标准治疗的复发或转移性妇科恶性肿瘤\",\n      \"联系人\": [\n        \"李 想\"\n      ],\n      \"联系电话\": [\n        \"17703993082\"\n      ]\n    }\n  },\n  {\n    \"id\": \"351\",\n    \"name\": \" 一项评价HSK39775片单药用于晚期实体恶性肿瘤患者中的安全性、耐受性、PK/PD特征及初步有效性的Ⅰ/Ⅱ期临床研究\",\n    \"phase\": \"Ⅰ期\",\n    \"conditions\": null,\n    \"line_of_therapy\": \"＞1线\",\n    \"biomarker\": null,\n    \"doctor\": \"李佳佳、刘汝娇\",\n    \"sponsor\": \"西藏海思科制药有限公司\",\n    \"lead_or_participation\": \"牵头\",\n    \"treatment\": \"HSK39775片（泛素特异性蛋白酶1抑制剂，USP1i）\",\n    \"key_inclusion\": \"既往接受过标准治疗或标准治疗不耐受或无标准治疗或无法获得标准治疗；\",\n    \"key_exclusion\": \"\",\n    \"contacts\": [\n      \"张倩野\"\n    ],\n    \"phones\": [\n      \"18627004197\"\n    ],\n    \"_raw\": {\n      \"id\": \"351\",\n      \"项目名称\": \" 一项评价HSK39775片单药用于晚期实体恶性肿瘤患者中的安全性、耐受性、PK/PD特征及初步有效性的Ⅰ/Ⅱ期临床研究\",\n      \"医生\": \"李佳佳、刘汝娇\",\n      \"试验治疗/用药\": \"HSK39775片（泛素特异性蛋白酶1抑制剂，USP1i）\",\n      \"期别\": \"Ⅰ期\",\n      \"申请单位\": \"西藏海思科制药有限公司\",\n      \"牵头/参与\": \"牵头\",\n      \"目标受试者治疗线数\": \"＞1线\",\n      \"入组排除标准\": \"既往接受过标准治疗或标准治疗不耐受或无标准治疗或无法获得标准治疗；\",\n      \"联系人\": [\n        \"张倩野\"\n      ],\n      \"联系电话\": [\n        \"18627004197\"\n      ]\n    }\n  },\n  {\n    \"id\": \"353\",\n    \"name\": \"在晚期恶性实体瘤患者中评价注射用西罗莫司（白蛋白结合型）的安全性、耐受性、药代动力学特征以及初步疗效的I期临床研究\",\n    \"phase\": \"Ⅰ期\",\n    \"conditions\": null,\n    \"line_of_therapy\": \"＞1线\",\n    \"biomarker\": null,\n    \"doctor\": \"刘汝娇\",\n    \"sponsor\": \" 石药集团中奇制药技术（石家庄）有限公司\",\n    \"lead_or_participation\": \"参与（天津市肿瘤医院 郝继辉）\",\n    \"treatment\": \"注射用西罗莫司（白蛋白结合型）\",\n    \"key_inclusion\": \"1、标准治疗失败或无标准治疗患者\",\n    \"key_exclusion\": \"\",\n    \"contacts\": [\n      \"刘 涵\"\n    ],\n    \"phones\": [\n      \"19109628595\"\n    ],\n    \"_raw\": {\n      \"id\": \"353\",\n      \"项目名称\": \"在晚期恶性实体瘤患者中评价注射用西罗莫司（白蛋白结合型）的安全性、耐受性、药代动力学特征以及初步疗效的I期临床研究\",\n      \"医生\": \"刘汝娇\",\n      \"试验治疗/用药\": \"注射用西罗莫司（白蛋白结合型）\",\n      \"期别\": \"Ⅰ期\",\n      \"申请单位\": \" 石药集团中奇制药技术（石家庄）有限公司\",\n      \"牵头/参与\": \"参与（天津市肿瘤医院 郝继辉）\",\n      \"目标受试者治疗线数\": \"＞1线\",\n      \"入组排除标准\": \"1、标准治疗失败或无标准治疗患者\",\n      \"联系人\": [\n        \"刘 涵\"\n      ],\n      \"联系电话\": [\n        \"19109628595\"\n      ]\n    }\n  },\n  {\n    \"id\": \"354\",\n    \"name\": \"一项评价注射用DR30206治疗晚期实体瘤患者的安全性、耐受性和药代动力学特征的多中心、开放性I期临床研究\",\n    \"phase\": \"Ⅰ期\",\n    \"conditions\": null,\n    \"line_of_therapy\": \"＞1线\",\n    \"biomarker\": null,\n    \"doctor\": \"吴 勇\",\n    \"sponsor\": \" 浙江道尔生物科技有限公司\",\n    \"lead_or_participation\": \"参与（组长单位：上海市肺科医院）\",\n    \"treatment\": \"注射用DR30206（靶向 PD-L1、VEGF 和 TGFβ 的抗体融合蛋白）\",\n    \"key_inclusion\": \"1、充分标准治疗失败或不耐受标准治疗或无有效标准治疗\\n\\n2、HPV 16+\",\n    \"key_exclusion\": \"\",\n    \"contacts\": [\n      \"浦东/郭 伟 、徐汇/江文艳\"\n    ],\n    \"phones\": [\n      \"13156793722、15664735519\"\n    ],\n    \"_raw\": {\n      \"id\": \"354\",\n      \"项目名称\": \"一项评价注射用DR30206治疗晚期实体瘤患者的安全性、耐受性和药代动力学特征的多中心、开放性I期临床研究\",\n      \"医生\": \"吴 勇\",\n      \"试验治疗/用药\": \"注射用DR30206（靶向 PD-L1、VEGF 和 TGFβ 的抗体融合蛋白）\",\n      \"期别\": \"Ⅰ期\",\n      \"申请单位\": \" 浙江道尔生物科技有限公司\",\n      \"牵头/参与\": \"参与（组长单位：上海市肺科医院）\",\n      \"目标受试者治疗线数\": \"＞1线\",\n      \"入组排除标准\": \"1、充分标准治疗失败或不耐受标准治疗或无有效标准治疗<br />\\r\\n2、HPV 16+<br />\",\n      \"联系人\": [\n        \"浦东/郭 伟 、徐汇/江文艳\"\n      ],\n      \"联系电话\": [\n        \"13156793722、15664735519\"\n      ]\n    }\n  },\n  {\n    \"id\": \"358\",\n    \"name\": \"评估JSKN033在中国晚期恶性实体瘤受试者中的安全性、耐受性、药代动力学/药效学以及抗肿瘤活性的I/II期临床研究\",\n    \"phase\": \"Ⅰ期\",\n    \"conditions\": null,\n    \"line_of_therapy\": \"2-3线\",\n    \"biomarker\": null,\n    \"doctor\": \"张 剑 、李佳佳\",\n    \"sponsor\": \"江苏康宁杰瑞生物制药有限公司\",\n    \"lead_or_participation\": \"牵头\",\n    \"treatment\": \"JSKN033注射液（HER2 双特异性抗体偶联药物（ADC，毒性分子：拓扑异构酶I 抑制剂）与 PD-L1 抑制剂的高浓度皮下注射复方制剂）\",\n    \"key_inclusion\": \"1、标准治疗失败或无标准治疗患者\",\n    \"key_exclusion\": \"\",\n    \"contacts\": [\n      \"徐汇/牛紫嫣 浦东/刘雅琦\"\n    ],\n    \"phones\": [\n      \"15638299516 18636833967 \"\n    ],\n    \"_raw\": {\n      \"id\": \"358\",\n      \"项目名称\": \"评估JSKN033在中国晚期恶性实体瘤受试者中的安全性、耐受性、药代动力学/药效学以及抗肿瘤活性的I/II期临床研究\",\n      \"医生\": \"张 剑 、李佳佳\",\n      \"试验治疗/用药\": \"JSKN033注射液（HER2 双特异性抗体偶联药物（ADC，毒性分子：拓扑异构酶I 抑制剂）与 PD-L1 抑制剂的高浓度皮下注射复方制剂）\",\n      \"期别\": \"Ⅰ期\",\n      \"申请单位\": \"江苏康宁杰瑞生物制药有限公司\",\n      \"牵头/参与\": \"牵头\",\n      \"目标受试者治疗线数\": \"2-3线\",\n      \"入组排除标准\": \"1、标准治疗失败或无标准治疗患者\",\n      \"联系人\": [\n        \"徐汇/牛紫嫣 浦东/刘雅琦\"\n      ],\n      \"联系电话\": [\n        \"15638299516 18636833967 \"\n      ]\n    }\n  },\n  {\n    \"id\": \"359\",\n    \"name\": \"SHR-4375注射液在晚期实体瘤患者中的安全性、耐受性、药代动力学及疗效的开放、单臂、多中心的I/II期临床研究\",\n    \"phase\": \"Ⅰ期\",\n    \"conditions\": null,\n    \"line_of_therapy\": \">2L\",\n    \"biomarker\": null,\n    \"doctor\": \"张 剑 、李佳佳 、刘汝娇、 高水平\",\n    \"sponsor\": \"苏州盛迪亚生物医药有限公司\",\n    \"lead_or_participation\": \"牵头\",\n    \"treatment\": \"SHR-4375（ADC ，靶向TF，毒性分子：拓扑异构酶I 抑制剂）\",\n    \"key_inclusion\": \"1、组织学确诊的子宫颈癌；\\n\\n2、标准治疗失败或无标准治疗患者\",\n    \"key_exclusion\": \"\",\n    \"contacts\": [\n      \"黄洋洋\"\n    ],\n    \"phones\": [\n      \"13226861415\"\n    ],\n    \"_raw\": {\n      \"id\": \"359\",\n      \"项目名称\": \"SHR-4375注射液在晚期实体瘤患者中的安全性、耐受性、药代动力学及疗效的开放、单臂、多中心的I/II期临床研究\",\n      \"医生\": \"张 剑 、李佳佳 、刘汝娇、 高水平\",\n      \"试验治疗/用药\": \"SHR-4375（ADC ，靶向TF，毒性分子：拓扑异构酶I 抑制剂）\",\n      \"期别\": \"Ⅰ期\",\n      \"申请单位\": \"苏州盛迪亚生物医药有限公司\",\n      \"牵头/参与\": \"牵头\",\n      \"目标受试者治疗线数\": \">2L\",\n      \"入组排除标准\": \"1、组织学确诊的子宫颈癌；<br />\\r\\n2、标准治疗失败或无标准治疗患者<br />\",\n      \"联系人\": [\n        \"黄洋洋\"\n      ],\n      \"联系电话\": [\n        \"13226861415\"\n      ]\n    }\n  },\n  {\n    \"id\": \"361\",\n    \"name\": \"一项旨在携带HER2激活突变的转移性或不可切除实体瘤参与者中评价口服可逆性酪氨酸激酶抑制剂BAY 2927088的有效性和安全性的II期、开放性、篮式研究\",\n    \"phase\": \"II期\",\n    \"conditions\": null,\n    \"line_of_therapy\": \"＞1线\",\n    \"biomarker\": null,\n    \"doctor\": \"李佳佳\",\n    \"sponsor\": \"Bayer Consumer Care AG\",\n    \"lead_or_participation\": \"参与\",\n    \"treatment\": \"单臂研究\\n\\nBAY 2927088（TKI，靶向HER2）\",\n    \"key_inclusion\": \"1、标准治疗失败或无标准治疗患者；\\n\\n2、HER2激活突变（本院或认证的机构）；\\n\\n3、需提供肿瘤组织切片。\",\n    \"key_exclusion\": \"\",\n    \"contacts\": [\n      \"李金山\"\n    ],\n    \"phones\": [\n      \"18893190113 \"\n    ],\n    \"_raw\": {\n      \"id\": \"361\",\n      \"项目名称\": \"一项旨在携带HER2激活突变的转移性或不可切除实体瘤参与者中评价口服可逆性酪氨酸激酶抑制剂BAY 2927088的有效性和安全性的II期、开放性、篮式研究\",\n      \"医生\": \"李佳佳\",\n      \"试验治疗/用药\": \"单臂研究<br />\\r\\nBAY 2927088（TKI，靶向HER2）<br />\",\n      \"期别\": \"II期\",\n      \"申请单位\": \"Bayer Consumer Care AG\",\n      \"牵头/参与\": \"参与\",\n      \"目标受试者治疗线数\": \"＞1线\",\n      \"入组排除标准\": \"1、标准治疗失败或无标准治疗患者；<br />\\r\\n2、HER2激活突变（本院或认证的机构）；<br />\\r\\n3、需提供肿瘤组织切片。<br />\",\n      \"联系人\": [\n        \"李金山\"\n      ],\n      \"联系电话\": [\n        \"18893190113 \"\n      ]\n    }\n  }\n]\n\nDECISION RULE (be conservative):\nRecommend ONE trial ONLY IF ALL are true:\n1) Cancer type / primary site clearly matches.\n2) Disease setting clearly matches (e.g., recurrent/advanced/metastatic and line is not fundamentally unclear).\n3) Required biomarker/subtype is explicitly present in case text (if trial requires it).\n4) No more than 2 critical eligibility confirmations remain.\n\nIf ANY of the above is not satisfied -> output None.\n\nOUTPUT TEMPLATE (EXACT; no extra text):\n\nTrial Recommendation:\n- id: <trial id or None>\n- name: <trial name or None>\n- Reason: <1 short sentence>\n- Missing eligibility confirmations (0-2 items):\n  - item1 (or \"None\")\n  - item2", "assistant_reply": "Trial Recommendation:\n- id: 350\n- name: 评价注射用BL-B01D1在复发或转移性妇科恶性肿瘤等多种实体瘤患者中的安全性、耐受性、药代动力学及有效性的Ib/II期临床研究\n- Reason: Recurrent metastatic ovarian clear cell carcinoma is a gynecologic malignancy after ≥1 prior standard therapy, matching this 2L–3L gynecologic trial without biomarker requirements.\n- Missing eligibility confirmations (0-2 items):\n  - Confirmation of ECOG performance status and other general organ function criteria\n  - Confirmation that there is no other available standard systemic therapy deemed appropriate by treating physician", "timestamp": "2026-01-21T07:03:33.589396"}]}, "trace_events": [{"ts": "2026-01-21T07:01:22.221310", "event": "pipeline_start", "payload": {"visit_time": "2023-01-03 08:53:29.260000", "meta_info": "340123197709263626"}}, {"ts": "2026-01-21T07:01:22.221880", "event": "case_fingerprint", "payload": {"case_fingerprint": "2a31f255c155"}}, {"ts": "2026-01-21T07:01:22.490094", "event": "reports_loaded", "payload": {"lab_n": 92, "img_n": 10, "path_n": 0, "mut_n": 1, "cutoff_dt": "2023-01-04 08:53:29"}}, {"ts": "2026-01-21T07:01:33.635211", "event": "reports_selected", "payload": {"lab": {"chair": ["20221229|8300002|2022-12-29", "20221229|9703212|2022-12-29", "20230103|5600862|2023-01-03"], "oncologist": ["20221229|8300002|2022-12-29", "20221229|9703212|2022-12-29", "20230103|5600862|2023-01-03"], "radiologist": [], "pathologist": [], "nuclear": []}, "imaging": {"chair": ["2022-10-24|MR|2022-10-24", "2022-12-29|MR|2022-12-29", "2022-12-29|CT|2022-12-29"], "oncologist": [], "radiologist": ["2022-10-24|MR|2022-10-24", "2022-12-29|MR|2022-12-29", "2022-12-29|CT|2022-12-29"], "pathologist": [], "nuclear": ["2022-10-24|MR|2022-10-24", "2022-12-29|MR|2022-12-29", "2022-12-29|CT|2022-12-29"]}, "pathology": {"chair": [], "oncologist": [], "radiologist": [], "pathologist": [], "nuclear": []}, "mutation": {"chair": ["OH2203828|2022-04-18"], "oncologist": ["OH2203828|2022-04-18"], "radiologist": [], "pathologist": ["OH2203828|2022-04-18"], "nuclear": []}}}, {"ts": "2026-01-21T07:01:33.640799", "event": "rag_key_facts", "payload": {"facts": "DIAGNOSIS: primary=卵巢癌复发; histology=透明细胞癌; 肠壁全层见高级别腺癌; components=High-grade adenocarcinoma involving full-thickness intestinal wall;Lymph node metastasis (4/15);Peritoneal/rectal/vaginal involvement described\nPATHOLOGY: Consider ovarian clear cell carcinoma involvement; full-thickness intestinal wall high-grade adenocarcinoma\nPLATINUM: status=Resistant; pfi_days=56\nBIOMARKERS: CA125=933.00 U/ml (2022-12-29); AFP=<0.91 ng/ml (2022-10-12); TMB=Unknown; MSI=Unknown; PDL1_CPS=Unknown\nMUTATION_REPORT: id=OH2203828; date=2022-04-18; full_text=ATM NM_000051:exon8:c.A947G:p.Y316C（胚系）；HRD 阴性；BRCA1 胚系和体系未检出致病突变（视为阴性）；BRCA2 胚系和体系未检出致病突变（视为阴性）；TP53 胚系和体系未检出致病突变（视为阴性）；ARID1A 胚系和体系未检出致病突变（视为阴性）；PTEN 胚系和体系未检出致病突变（视为阴性）；PIK3CA 胚系和体系未检出致病突变（视为阴性）；PALB2 胚系和体系未检出致病突变（视为阴性）；RAD51D 胚系和体系未检出致病突变（视为阴性）；BRIP1 胚系和体系未检出致病突变（视为阴性）；BARD1 胚系和体系未检出致病突变（视为阴性）"}}, {"ts": "2026-01-21T07:01:43.413272", "event": "rag_query", "payload": {"query": "Recurrent platinum-resistant ovarian clear cell carcinoma with pelvic, presacral, liver and possible bone metastases; Ki-67 60%; HRD-negative, BRCA1/2-negative, germline ATM p.Y316C; no major organ dysfunction reported; histology: clear cell carcinoma"}}, {"ts": "2026-01-21T07:01:43.413276", "event": "rag_hits", "payload": {"source": "guideline", "topk": 5, "n": 5}}, {"ts": "2026-01-21T07:01:43.413278", "event": "rag_hits", "payload": {"source": "pubmed", "topk": 5, "n": 5}}, {"ts": "2026-01-21T07:01:43.413279", "event": "rag_hits_merged", "payload": {"n": 10}}, {"ts": "2026-01-21T07:01:54.042486", "event": "mdt_discussion_start", "payload": {"num_rounds": 2, "num_turns": 2}}, {"ts": "2026-01-21T07:01:54.042562", "event": "mdt_initial_opinion_role_start", "payload": {"role": "chair", "order": 1}}, {"ts": "2026-01-21T07:01:57.709455", "event": "mdt_initial_opinion_role_end", "payload": {"role": "chair", "chars": 563}}, {"ts": "2026-01-21T07:01:57.709508", "event": "mdt_initial_opinion_role_start", "payload": {"role": "oncologist", "order": 2}}, {"ts": "2026-01-21T07:02:00.409664", "event": "mdt_initial_opinion_role_end", "payload": {"role": "oncologist", "chars": 628}}, {"ts": "2026-01-21T07:02:00.409728", "event": "mdt_initial_opinion_role_start", "payload": {"role": "radiologist", "order": 3}}, {"ts": "2026-01-21T07:02:02.651158", "event": "mdt_initial_opinion_role_end", "payload": {"role": "radiologist", "chars": 576}}, {"ts": "2026-01-21T07:02:02.651231", "event": "mdt_initial_opinion_role_start", "payload": {"role": "pathologist", "order": 4}}, {"ts": "2026-01-21T07:02:05.922694", "event": "mdt_initial_opinion_role_end", "payload": {"role": "pathologist", "chars": 442}}, {"ts": "2026-01-21T07:02:05.922792", "event": "mdt_initial_opinion_role_start", "payload": {"role": "nuclear", "order": 5}}, {"ts": "2026-01-21T07:02:08.063994", "event": "mdt_initial_opinion_role_end", "payload": {"role": "nuclear", "chars": 510}}, {"ts": "2026-01-21T07:03:30.108036", "event": "mdt_discussion_end", "payload": {"merged_chars": 2583}}, {"ts": "2026-01-21T07:03:30.109297", "event": "trial_matching_start", "payload": {"trials_json_path": "files/all_trials_filtered.json"}}, {"ts": "2026-01-21T07:03:33.589466", "event": "trial_matching_end", "payload": {"recommended": true}}, {"ts": "2026-01-21T07:03:33.589483", "event": "final_output_start", "payload": {}}, {"ts": "2026-01-21T07:03:43.288680", "event": "final_output_end", "payload": {"final_output_chars": 3095}}], "trace_mermaid": "flowchart TD\n  A[Load Case + Fingerprint] --> B[Load Reports]\n  B --> C[Report Selection per Role]\n  C --> D[Guideline+PubMed RAG]\n  D --> E[Init Specialist Agents]\n  E --> F[MDT Discussion Engine]\n  F --> G[Trial Matching]\n  G --> H[Final Chair Output]\n  H --> I[Save Logs]\n"}
